[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 242
1. van Agthoven M, Sonneveld P, Verdonck LF, Uyl-de Groot CA: Cost determinants in aggressive non-Hodgkin's lymphoma. Haematologica; 2005 May;90(5):661-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost determinants in aggressive non-Hodgkin's lymphoma.
  • BACKGROUND AND OBJECTIVES: The 5 factors of the International Prognostic Index (IPI) for aggressive non Hodgkin's lymphoma (NHL) age, disease stage, serum lactate dehydrogenase (LDH), performance status, number of extranodal sites) are validated predictors of a patient's survival.
  • DESIGN AND METHODS: Chart data for 374 patients with newly diagnosed stage II-IV aggressive NHL treated between 1993-2001 with CHOP chemotherapy were used.
  • Regression analyses and non-parametric bootstrap tests were performed to determine the significance of prognostic factors.
  • [MeSH-major] Health Care Costs. Lymphoma, Non-Hodgkin / economics
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Antineoplastic Combined Chemotherapy Protocols / economics. Child. Combined Modality Therapy / economics. Cost-Benefit Analysis. Costs and Cost Analysis. Drug Costs. Female. Fever / epidemiology. Follow-Up Studies. Granulocyte Colony-Stimulating Factor / economics. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Neoplasm Proteins / blood. Netherlands / epidemiology. Prognosis. Radiotherapy, Adjuvant / economics. Retrospective Studies. Risk Factors. Severity of Illness Index. Survival Analysis. Sweating. Weight Loss

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921381.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


2. Guney N, Soydinc HO, Basaran M, Bavbek S, Derin D, Camlica H, Yasasever V, Topuz E: Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma. Asian Pac J Cancer Prev; 2009 Oct-Dec;10(4):669-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma.
  • This study was conducted to investigate the serum levels of IL-6 and IL-10 in patients with aggressive non-Hodgkin's lymphoma (A-NHL) and the relationships with prognostic parameters and therapy.
  • [MeSH-major] Biomarkers, Tumor / blood. Interleukin-10 / blood. Interleukin-6 / blood. Lymphoma, Non-Hodgkin / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Enzyme-Linked Immunosorbent Assay. Female. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Turkey. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19827892.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-6; 130068-27-8 / Interleukin-10; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


3. Pelosi E, Penna D, Deandreis D, Chiappella A, Skanjeti A, Vitolo U, Bisi G: FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management. Q J Nucl Med Mol Imaging; 2008 Mar;52(1):9-16
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
  • AIM: Identification of bone marrow disease (BMD) is a crucial step in the diagnostic work-up of patients with lymphoma.
  • In lymphoma staging, bone marrow biopsy (BMb) is considered as the gold standard, despite its limitations.
  • The aim of this study was to compare the usefulness of 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography (FDG-PET) vs BMb in the detection of BMD in patients with Hodgkin's disease (HL) or aggressive non-Hodgkin's lymphoma (NHL) and its impact on therapy.
  • METHODS: A total of 194 consecutive patients with malignant lymphoma were referred for staging.
  • [MeSH-major] Bone Marrow Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Hodgkin Disease / radionuclide imaging. Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Bone Marrow / pathology. Bone Marrow / radionuclide imaging. Child. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18235420.001).
  • [ISSN] 1824-4785
  • [Journal-full-title] The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
  • [ISO-abbreviation] Q J Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


Advertisement
4. Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, Lee CR, Taylor D, Zhang L, Man S, Baruchel S, Stempak D, Bertolini F, Crump M: High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res; 2006 Sep 1;12(17):5190-8
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
  • PURPOSE: Angiogenesis is increased in aggressive histology non-Hodgkin's lymphoma and may be a target with selective cyclooxygenase-2 inhibition and metronomic chemotherapy.
  • EXPERIMENTAL DESIGN: We assessed response, toxicity, and biomarkers of angiogenesis to low-dose cyclophosphamide (50 mg p.o. o.d.) and high-dose celecoxib (400 mg p.o. b.i.d.) in adult patients with relapsed or refractory aggressive non-Hodgkin's lymphoma in a multicenter phase II prospective study.
  • Patients had primarily relapsed diffuse large B-cell lymphoma (63%) were heavily pretreated (median of three regimens) and high risk (79% international prognostic index, >or=2) and 34% were relapsed after autologous stem cell transplant.
  • CONCLUSIONS: Low-dose cyclophosphamide and high-dose celecoxib is well tolerated and active in pretreated aggressive non-Hodgkin's lymphoma.
  • [MeSH-major] Cyclophosphamide / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Pyrazoles / administration & dosage. Sulfonamides / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Celecoxib. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug-Related Side Effects and Adverse Reactions. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Maximum Tolerated Dose. Middle Aged. Prospective Studies. Recurrence. Risk Factors. Survival Rate. Treatment Outcome. Vascular Endothelial Growth Factor A / blood

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16951238.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyrazoles; 0 / Sulfonamides; 0 / Vascular Endothelial Growth Factor A; 8N3DW7272P / Cyclophosphamide; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


5. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM: Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol; 2008 Oct 20;26(30):4952-7
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
  • PURPOSE: The major cause of death in aggressive lymphoma is relapse or nonresponse to initial therapy.
  • Lenalidomide has activity in a variety of hematologic malignancies, including non-Hodgkin's lymphoma (NHL).
  • We report the results of a phase II, single-arm, multicenter trial evaluating the safety and efficacy of lenalidomide oral monotherapy in patients with relapsed or refractory aggressive NHL.
  • The most common histology was diffuse large B-cell lymphoma (53%), and patients had received a median of four prior treatment regimens for NHL.
  • Responses were observed in each aggressive histologic subtype tested (diffuse large B-cell, follicular center grade 3, mantle cell, and transformed lymphomas).
  • CONCLUSION: Oral lenalidomide monotherapy is active in relapsed or refractory aggressive NHL, with manageable side effects.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Neoplasm Recurrence, Local / drug therapy. Thalidomide / analogs & derivatives
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Hematologic Diseases / chemically induced. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Mantle-Cell / drug therapy. Male. Middle Aged. Prospective Studies. Remission Induction


6. Akoum R, Brihi E, Saade M, Hanna T, Chahine G: Salvage abdominal irradiation for refractory non-Hodgkin's lymphoma. J Cancer Res Ther; 2007 Jul-Sep;3(3):143-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage abdominal irradiation for refractory non-Hodgkin's lymphoma.
  • BACKGROUND: Abdominal irradiation, as a part of treatment, is often ignored in the management of refractory non-Hodgkin's lymphoma (NHL).
  • MATERIALS AND METHODS: 27 patients with intraabdominal lymphoma underwent salvage irradiation between 1982 and 2001.
  • Thirteen patients, six with follicular and seven with aggressive tumors, had refractory relapsed tumors after achieving one or more complete remissions.
  • Survival rates were significantly better for patients with refractory relapse compared to those with primary refractory lymphoma (P < 0.01).
  • There was no significant difference in terms of response, recurrence, or survival rates between follicular and aggressive types.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy. Salvage Therapy
  • [MeSH-minor] Abdomen. Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079576.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


7. Laatiri MA, Elloumi M, Ali ZB, Ben Othmen T, Msadek F, Toumi N, Bouaouina N, Daoud J, Maalej M, Ghannem H, Meddeb B: [Tunisian experience in the treatment of aggressive non Hodgkin's lymphoma in adults: about 337 patients]. Bull Cancer; 2010 Apr;97(4):409-16
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tunisian experience in the treatment of aggressive non Hodgkin's lymphoma in adults: about 337 patients].
  • From January 1997 to December 2005, 337 patients with aggressive non Hodgkin's lymphoma were treated with one of the two successive multicentric non randomized protocols established in Tunisia.
  • Most patients had diffuse large cell lymphoma with B phenotype in 86% and T in 14%.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Epirubicin / administration & dosage. Etoposide / administration & dosage. Female. Hematopoietic Stem Cell Transplantation / methods. Humans. Karnofsky Performance Status. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Male. Middle Aged. Prednisolone / administration & dosage. Prednisone / administration & dosage. Prospective Studies. Remission Induction / methods. Rituximab. Stem Cell Transplantation. Survival Analysis. Tunisia. Vincristine / administration & dosage. Young Adult

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20374978.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 3Z8479ZZ5X / Epirubicin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone; CEOP protocol 2; CHOEP protocol; CHOP protocol
  •  go-up   go-down


8. Ruan J, Hyjek E, Kermani P, Christos PJ, Hooper AT, Coleman M, Hempstead B, Leonard JP, Chadburn A, Rafii S: Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma. Clin Cancer Res; 2006 Oct 1;12(19):5622-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma.
  • Here, we investigated whether stromal incorporation of CD68(+) hemangiogenic cells and alpha-smooth muscle actin(+) (alpha-SMA(+)) stromal cells correlates with neoangiogenesis and progression in human non-Hodgkin's lymphoma subtypes.
  • EXPERIMENTAL DESIGN: Spatial localizations of vascular and stromal cells expressing CD34, VEGFR-1, alpha-SMA, and CD68 were examined by immunohistochemistry in 42 cases of non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma, Burkitt lymphoma, follicular lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and compared with benign follicular hyperplasia.
  • RESULTS: Compared with indolent lymphomas, there was a profound increase in recruitment of CD68(+) cells and VEGFR-1(+) neovessels in aggressive subtypes (including those transformed from indolent subtypes), where CD68(+) cells were localized to the perivascular region of neovessels as well as the stromal compartment.
  • In contrast, there was a diffuse increase in alpha-SMA incorporation throughout the stromal compartment of indolent subtype of CLL/SLL compared with the scant perivascular pattern in aggressive subtypes.
  • Overall, there was no correlation between CD34(+) microvessel density and lymphoma histologic subtype.
  • CONCLUSIONS: Heightened stromal hemangiogenesis as marked by infiltration of proangiogenic VEGFR-1(+)CD68(+)VEGF-A(+) cells and their paracrine cross-talk with neovasculature appears to be a distinct feature of aggressive lymphoma, providing novel targets for antiangiogenic therapy, whereas alpha-SMA(+) stromal vascular network may be differentially targeted in CLL/SLL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Neovascularization, Pathologic / pathology. Stromal Cells / pathology
  • [MeSH-minor] Actins / metabolism. Adult. Aged. Aged, 80 and over. Antigens, CD / metabolism. Antigens, CD34 / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / pathology. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, Follicular / metabolism. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Microcirculation. Middle Aged. Muscle, Smooth / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor Receptor-1 / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17020964.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL 075234; United States / NHLBI NIH HHS / HL / HL 59312; United States / NHLBI NIH HHS / HL / HL 67839; United States / NCRR NIH HHS / RR / K23 RR 016814
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


9. Jacobsen E, LaCasce A: Update on the therapy of highly aggressive non-Hodgkin's lymphoma. Expert Opin Biol Ther; 2006 Jul;6(7):699-708
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on the therapy of highly aggressive non-Hodgkin's lymphoma.
  • This review focuses on the current understanding of the biology of highly aggressive non-Hodgkin's lymphomas, such as Burkitt's lymphoma, lymphoblastic lymphoma and adult T cell lymphoma/leukaemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma. Lymphoma, Non-Hodgkin. Lymphoma, T-Cell. Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adult. Child. Female. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16805709.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 95
  •  go-up   go-down


10. Hayashi D, Lee JC, Devenney-Cakir B, Zaim S, Ounadjela S, Solal-Céligny P, Juweid M, Guermazi A: Follicular non-Hodgkin's lymphoma. Clin Radiol; 2010 May;65(5):408-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular non-Hodgkin's lymphoma.
  • Follicular non-Hodgkin's lymphoma (NHL) is a unique subtype of NHL, which is indolent, incurable with a high prevalence of residual mass after treatment, and may transform to more aggressive NHL.
  • (2) introduce the Follicular Lymphoma International Prognostic Index 2 (FLIPI-2), which allows better treatment selection and patient stratification for clinical trials;.
  • Imaging is essential in every step of the management of patients with follicular lymphoma.
  • Radiologists should be aware of possible active residual mass, indolent recurrence, transformation, and association with other primary cancers in patients treated for follicular lymphoma.
  • [MeSH-major] Diagnostic Imaging / methods. Lymphoma, Follicular / diagnosis
  • [MeSH-minor] Adult. Aged. Cell Transformation, Neoplastic / pathology. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Staging / methods. Neoplasm, Residual. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / pathology. Prognosis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20380942.001).
  • [ISSN] 1365-229X
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 24
  •  go-up   go-down


11. Schöder H, Noy A, Gönen M, Weng L, Green D, Erdi YE, Larson SM, Yeung HW: Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol; 2005 Jul 20;23(21):4643-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.
  • PURPOSE: (18)Fluorodeoxyglucose positron emission tomography (FDG PET) is widely used for the staging of lymphoma.
  • We investigated whether the intensity of tumor FDG uptake could differentiate between indolent and aggressive disease.
  • MATERIALS AND METHODS: PET studies of 97 patients with non-Hodgkin's lymphoma who were untreated or had relapsed and/or persistent disease and had not received treatment within the last 6 months were analyzed, and the highest standardized uptake value (SUV) per study was recorded.
  • RESULTS: FDG uptake was lower in indolent than in aggressive lymphoma for patients with new (SUV, 7.0 +/- 3.1 v 19.6 +/- 9.3; P < .01) and relapsed (SUV, 6.3 +/- 2.7 v 18.1 +/- 10.9; P = .04) disease.
  • Despite overlap between indolent and aggressive disease in the low SUV range (indolent, 2.3 to 13.0; aggressive, 3.2 to 43.0), all cases of indolent lymphoma had an SUV <or= 13.
  • A receiver operating characteristic (ROC) analysis demonstrated that the SUV distinguished reasonably well between aggressive and indolent disease (area under ROC curve, 84.7%), and an SUV > 10 excluded indolent lymphoma with a specificity of 81%.
  • CONCLUSION: FDG uptake is lower in indolent than in aggressive lymphoma.
  • Patients with NHL and SUV > 10 have a high likelihood for aggressive disease.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Radiopharmaceuticals / pharmacokinetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Jul 20;23(21):4577-80 [15837974.001]
  • (PMID = 15837966.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


12. Elis A, Tevet A, Yerushalmi R, Blickstein D, Bairy O, Dann EJ, Blumenfeld Z, Abraham A, Manor Y, Shpilberg O, Lishner M: Fertility status among women treated for aggressive non-Hodgkin's lymphoma. Leuk Lymphoma; 2006 Apr;47(4):623-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility status among women treated for aggressive non-Hodgkin's lymphoma.
  • In young women treated for intermediate-high-grade non-Hodgkin's lymphoma with CHOP (cyclophosphamide, adriamycin, oncovine and prednisone), there is insufficient data concerning gonadotoxicity or the need for fertility-preserving measures.
  • The aim of the present study was to evaluate the fertility status in the first complete remission of women who were treated for aggressive non-Hodgkin's lymphoma.
  • A cohort of 36 women with aggressive non-Hodgkin's lymphoma in first remission, who were treated in five university-affiliated hospitals in Israel, was evaluated.
  • In conclusion, the rate of gonadal dysfunction is very low among young, CHOP treated, non-Hodgkin's lymphoma female patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Fertility. Infertility, Female / etiology. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / pathology. Menstrual Cycle / drug effects
  • [MeSH-minor] Adolescent. Adult. Amenorrhea. Cohort Studies. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Female. Humans. Kinetics. Prednisone / adverse effects. Prednisone / therapeutic use. Remission Induction. Risk. Time Factors. Vincristine / adverse effects. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Female Infertility.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Apr;47(4):574-5 [16886268.001]
  • (PMID = 16690520.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


13. Smith SM, Johnson JL, Niedzwiecki D, Eder JP, Canellos G, Cheson BD, Bartlett NL, Cancer and Leukemia Group B: Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906. Leuk Lymphoma; 2006 Aug;47(8):1511-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906.
  • Patients with relapsed or refractory aggressive non-Hodgkin's lymphomas (NHL) were eligible for this phase II study of doxorubicin 25 mg/m2 intravenous (IV) on day 1 and topotecan 1.75 mg/m2/day IV on days 3 - 5, every 21 days.
  • Both patients achieving a complete remission had Burkitt's lymphoma.
  • The activity in Burkitt's lymphoma should be investigated further.
  • [MeSH-major] Doxorubicin / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Salvage Therapy / methods. Topotecan / administration & dosage
  • [MeSH-minor] Adult. Aged. Burkitt Lymphoma / drug therapy. Disease-Free Survival. Enzyme Inhibitors / administration & dosage. Enzyme Inhibitors / therapeutic use. Female. Humans. Male. Middle Aged. Recurrence. Remission Induction. Topoisomerase I Inhibitors

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966261.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA07968; United States / NCI NIH HHS / CA / CA08025; United States / NCI NIH HHS / CA / CA12046; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / CA86726
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Topoisomerase I Inhibitors; 7M7YKX2N15 / Topotecan; 80168379AG / Doxorubicin
  •  go-up   go-down


14. Mukherji D, Pettengell R: Pixantrone maleate for non-Hodgkin's lymphoma. Drugs Today (Barc); 2009 Nov;45(11):797-805
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pixantrone maleate for non-Hodgkin's lymphoma.
  • The PIX301 phase III single-agent trial of pixantrone for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma randomized patients to receive either pixantrone or another single agent of the investigators' choice.
  • There is evidence that pixantrone is well tolerated when substituted for anthracyclines in combination regimens for aggressive non-Hodgkin's lymphoma with comparable rates of complete remission.
  • Pixantrone has also been used for the treatment of indolent non-Hodgkin's lymphomas and the combination of pixantrone and rituximab has been shown to be superior to rituximab alone in relapsed or refractory disease in the phase III PIX302 study.
  • On the basis of these data, the United States Food and Drug Administration is considering pixantrone for use in adult patients with relapsed or refractory aggressive and indolent non-Hodgkin's lymphoma on a fast-track basis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Isoquinolines / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Animals. Clinical Trials as Topic. Drug Evaluation, Preclinical. Humans. Topoisomerase II Inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Prous Science, S.A.U. or its licensors. All rights reserved.
  • (PMID = 20126672.001).
  • [ISSN] 1699-3993
  • [Journal-full-title] Drugs of today (Barcelona, Spain : 1998)
  • [ISO-abbreviation] Drugs Today
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Isoquinolines; 0 / Topoisomerase II Inhibitors; F5SXN2KNMR / pixantrone
  • [Number-of-references] 31
  •  go-up   go-down


15. García Ortiz LM, Jaume Anselmi F, Ramírez Rivera J, Casiano Quiles W, Márquez Santiago R: Non-Hodgkin's lymphoma presenting as ulcerative colitis. Bol Asoc Med P R; 2006 Apr-Jun;98(2):140-3
MedlinePlus Health Information. consumer health - Ulcerative Colitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma presenting as ulcerative colitis.
  • High-grade Non-Hodgkin's lymphomas are very aggressive type of malignancies.
  • We report a high grade small B-cell (Burkitt's like) Non-Hodgkin's lymphoma that initially was considered and treated as ulcerative colitis without improvement or resolution of symptoms for nine months.
  • [MeSH-major] Colitis, Ulcerative / etiology. Lymphoma, Non-Hodgkin / complications
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19606804.001).
  • [ISSN] 0004-4849
  • [Journal-full-title] Boletín de la Asociación Médica de Puerto Rico
  • [ISO-abbreviation] Bol Asoc Med P R
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Puerto Rico
  •  go-up   go-down


16. Al-Mansour M, Connors JM, Gascoyne RD, Skinnider B, Savage KJ: Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol; 2010 Feb 10;28(5):793-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma.
  • PURPOSE Prior observations suggest a higher risk of transformation of nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) to aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL), than in classical Hodgkin's lymphoma.
  • With a median follow-up time for living patients of 6.5 years (range, 2.5 to 33 years), 13 patients (14%) experienced transformation to aggressive lymphoma (median time to transformation, 8.1 years; range, 0.35 to 20.3 years).
  • The actuarial risk of transformation to aggressive lymphoma was 7% and 30% at 10 and 20 years, respectively.
  • The 10-year progression-free and overall survival rates in patients with transformed lymphoma were 52% and 62%, respectively.
  • [MeSH-major] Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasms, Second Primary
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy. British Columbia / epidemiology. Databases as Topic. Disease Progression. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness. Proportional Hazards Models. Risk Assessment. Risk Factors. Time Factors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20048177.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


17. Tsartsidze E, Betaneli M: Prognostic significance of immunophenotype in aggressive non-Hodgkin's lymphoma. Georgian Med News; 2006 May;(134):107-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of immunophenotype in aggressive non-Hodgkin's lymphoma.
  • The purpose of the study was to evaluate prognostic value of immunophenotype in aggressive Non-Hodgkin's lymphoma.
  • 87 patients with immunohistologically confirmed diagnosis of aggressive Non-Hodgkin's lymphoma according to the WHO classification (2001) were under observation.
  • T-cell phenotype should be considered as an independent factor that strongly influences the survival for patients with diagnosis of aggressive non-Hodgkin's lymphomas.
  • [MeSH-major] B-Lymphocytes / immunology. Immunophenotyping. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / mortality. T-Lymphocytes / immunology
  • [MeSH-minor] Adult. Humans. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16783081.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  •  go-up   go-down


18. Colovic N, Jurisic V, Terzic T, Atkinson HD, Colovic M: Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin's lymphoma. Arch Dermatol Res; 2009 Oct;301(9):689-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin's lymphoma.
  • The case of a 44-year-old man with a primary cutaneous large B-cell non-Hodgkin's lymphoma of the scalp is reported.
  • His mother died of gastric lymphoma and his sib brother is in a 20-year remission of T-cell lymphoma.
  • The histopathology and immunohistochemistry performed in April 2006 indicated a bcl-6+, MUM- and bcl-2-, primary cutaneous follicle center B-cell non-Hodgkin's lymphoma, with an aggressive transformation to a diffuse large B-cell lymphoma.
  • Bone marrow biopsy and CT chest, abdomen, and pelvis were negative for systemic lymphoma.
  • The protracted indolent phase of the disease, the familial history of lymphoma, the histological aggressive features and the patient's excellent response to immunochemotherapy all contribute to a very unusual manifestation of this disease.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antigens, Neoplasm / metabolism. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Immunotherapy. Injections, Intravenous. Male. Prednisone / therapeutic use. Proto-Oncogene Proteins c-bcl-2 / metabolism. Rituximab. Treatment Outcome. Vesicular Transport Proteins / metabolism. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19495780.001).
  • [ISSN] 1432-069X
  • [Journal-full-title] Archives of dermatological research
  • [ISO-abbreviation] Arch. Dermatol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / BCL2L15 protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / TRAPPC1 protein, human; 0 / Vesicular Transport Proteins; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


19. Soliman KB, Abbas MM, Seksaka MA, Wafa S, Balah AS: Aggressive primary thyroid non Hodgkin's lymphoma with pregnancy. Saudi Med J; 2007 Apr;28(4):634-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive primary thyroid non Hodgkin's lymphoma with pregnancy.
  • She was diagnosed as an aggressive non-Hodgkin lymphoma of the thyroid gland.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Pregnancy Complications, Neoplastic. Thyroid Neoplasms / drug therapy
  • [MeSH-minor] Adult. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Prednisone / therapeutic use. Pregnancy. Pregnancy Outcome. Vincristine / therapeutic use


20. Jacomet C, Lesens O, Villemagne B, Darcha C, Tournilhac O, Henquell C, Cormerais L, Gourdon F, Peigue-Lafeuille H, Travade P, Beytout J, Laurichesse H: [Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003]. Med Mal Infect; 2006 Mar;36(3):157-62
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003].
  • [Transliterated title] Lymphomes non hodgkiniens et hodgkiniens et infection VIH: fréquence, pronostic et reconstitution immune sous trithérapie antirétrovirale; CHU de Clermont-Ferrand, 1991-2003.
  • OBJECTIVES: The authors had for aim to identify cases of non Hodgkin's (NHL) and Hodgkin's (HL) lymphomas in HIV1-infected patients to assess 1) their incidence, before and after 1996, 2) the clinical features and outcome under treatment together with the survival rate of the patients, 3) the immune reconstitution of lymphoma-free patients under HAART.
  • A high proportion of aggressive and disseminated disease was observed among NHL cases.
  • The mean survival was 109+/-54 months and was correlated with CD4 cell count at lymphoma diagnosis (univariate analysis).
  • Immune restoration in lymphoma-free patients under HAART is poor.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. HIV-1. Hodgkin Disease / epidemiology. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] AIDS-Related Opportunistic Infections / epidemiology. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CD4 Lymphocyte Count. Cohort Studies. Female. France / epidemiology. Hospitals, University / statistics & numerical data. Humans. Incidence. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome


21. Querellou S, Valette F, Bodet-Milin C, Oudoux A, Carlier T, Harousseau JL, Chatal JF, Couturier O: FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease. Ann Hematol; 2006 Nov;85(11):759-67
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
  • Early therapy response assessment with metabolic imaging is potentially useful to determine prognosis in aggressive lymphoma and, thus, can guide first-line therapy.
  • Forty-eight patients with aggressive lymphoma [24 Hodgkin's disease (HD); 24 non-Hodgkin's lymphoma (NHL)] underwent fluoro-deoxyglucose positron emission tomography (FDG-PET) before chemotherapy (PET1) and at mid-treatment (PET2).
  • FDG-PET at mid-treatment can predict the outcome of patients with aggressive lymphoma and should be a useful tool to modify an ineffective therapy.
  • [MeSH-major] Hodgkin Disease / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Positron-Emission Tomography / methods. Predictive Value of Tests. Tomography, Emission-Computed / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Remission Induction. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16871391.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


22. Hirose A, Yamane T, Nakajima Y, Manabe M, Kanashima H, Hagihara K, Sakamoto E, Nakamae M, Terada Y, Kosaka S, Aoyama Y, Sakamoto C, Kumura T, Koh KR, Hirai M, Ohta K, Nakao Y, Mugitani A, Teshima H, Hino M: [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma]. Gan To Kagaku Ryoho; 2005 Dec;32(13):2059-64
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma].
  • To evaluate the results of high-dose chemotherapy (HDT) and autologous hematopoietic stem cell transplantation (ASCT) in patients with diffuse B-cell aggressive non-Hodgkin's lymphoma(NHL).
  • HDT-ASCT should be considered for patients with refractory aggressive NHL who are chemotherapy-sensitive rather than chemotherapy-resistant.
  • In future, HDT-ASCT combined with rituximab as induction therapy or as consolidation therapy is needed for patients with aggressive NHL in the high-risk group.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Transplantation, Autologous
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Nitrosourea Compounds / administration & dosage. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16352929.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Nitrosourea Compounds; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; RYH2T97J77 / ranimustine
  •  go-up   go-down


23. Brepoels L, Stroobants S, De Wever W, Spaepen K, Vandenberghe P, Thomas J, Uyttebroeck A, Mortelmans L, De Wolf-Peeters C, Verhoef G: Aggressive and indolent non-Hodgkin's lymphoma: response assessment by integrated international workshop criteria. Leuk Lymphoma; 2007 Aug;48(8):1522-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive and indolent non-Hodgkin's lymphoma: response assessment by integrated international workshop criteria.
  • Until recently, response assessment in patients with lymphoma was primarily performed by computed tomography (CT).
  • Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) is a more sensitive and specific imaging technique for the detection of residual disease in lymphoma, and Revised Integrated International Workshop Criteria (IWC + PET) were recently proposed by the members of the International Harmonization Project (IHP), which combine both imaging techniques.
  • We determined whether these new IWC + PET-criteria, can more accurately predict outcome compared to IWC-criteria in aggressive and indolent non-Hodgkin's lymphoma (NHL), and therefore correlated IWC and IWC + PET response with time-to-next-treatment (TNT) in 69 patients with NHL.
  • We demonstrated that IWC + PET-guidelines are highly recommended over IWC-guidelines for patients with potentially-curable and routinely FDG-avid lymphoma.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Aged. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / radiography. Burkitt Lymphoma / radionuclide imaging. Humans. International Cooperation. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiography. Lymphoma, B-Cell / radionuclide imaging. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / radiography. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Middle Aged. Neoplasm Recurrence, Local / etiology. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / etiology. Neoplasms, Second Primary / pathology. Practice Guidelines as Topic. Predictive Value of Tests. Sensitivity and Specificity. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17701583.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


24. Schütt P, Zimmermann K, Derks C, Ebeling P, Welt A, Poser M, Hense J, Metz K, Anhuf J, Sandmann M, Neise M, Moritz T, Stuschke M, Niederle N, Seeber S, Nowrousian MR: Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphoma. J Cancer Res Clin Oncol; 2009 Mar;135(3):459-66
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphoma.
  • INTRODUCTION: Anthracyline-based chemotherapy is the treatment of choice for patients with aggressive B-cell non-Hodgkin's lymphoma (NHL).
  • METHODS: We conducted a study using a sequential combination chemotherapy with a reduced cumulative dose of anthracyclines in younger patients with good-prognosis aggressive NHL.
  • Consolidating involved-field irradiation was applied in patients with stage I/II, bulky disease, or localized residual lymphoma.
  • [MeSH-major] Anthracyclines / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / toxicity. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal / toxicity. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Antineoplastic Agents / toxicity. Cyclophosphamide / administration & dosage. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prognosis. Remission Induction. Rituximab. Survival Analysis. Survivors. Vincristine / administration & dosage. Young Adult

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):257-67 [8558207.001]
  • [Cites] Ann Intern Med. 1990 Oct 15;113(8):619-27 [2205142.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1067-73 [11583187.001]
  • [Cites] Cancer Res. 1986 Jul;46(7):3722-7 [3458531.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):536-41 [16098067.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1864-71 [15143078.001]
  • [Cites] Blood. 2004 May 15;103(10):3684-8 [14739217.001]
  • [Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2070-9 [9626206.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):277-81 [12562656.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2912-9 [16339404.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3776-85 [10577849.001]
  • [Cites] Ann Oncol. 2006 Apr;17(4):614-22 [16423847.001]
  • [Cites] Eur J Haematol. 2007 Feb;78(2):93-101 [17313557.001]
  • [Cites] Tumori. 2007 Sep-Oct;93(5):409-16 [18038870.001]
  • [Cites] Ann Oncol. 1993 May;4(5):359-69 [8353070.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • (PMID = 18758815.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


25. Quijano S, López A, Manuel Sancho J, Panizo C, Debén G, Castilla C, Antonio García-Vela J, Salar A, Alonso-Vence N, González-Barca E, Peñalver FJ, Plaza-Villa J, Morado M, García-Marco J, Arias J, Briones J, Ferrer S, Capote J, Nicolás C, Orfao A, Spanish Group for the Study of CNS Disease in NHL: Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol; 2009 Mar 20;27(9):1462-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry.
  • PURPOSE: Here, we evaluate the sensitivity and specificity of a new 11-parameter flow cytometry (FCM) approach versus conventional cytology (CC) for detecting neoplastic cells in stabilized CSF samples from newly diagnosed aggressive B-cell non-Hodgkin's lymphoma (B-NHL) at high risk of CNS relapse, using a prospective, multicentric study design.
  • Interestingly, in Burkitt lymphoma, presence of CNS disease by FCM could be predicted with a high specificity when increased serum beta2-microglobulin and neurological symptoms coexisted, while peripheral blood involvement was the only independent parameter associated with CNS disease in diffuse large B-cell lymphoma, with low predictive value.
  • CONCLUSION: FCM significantly improves the sensitivity of CC for the identification of leptomeningeal disease in aggressive B-NHL at higher risk of CNS disease, particularly in paucicellular samples.
  • [MeSH-major] Flow Cytometry / methods. Lymphoma, B-Cell / cerebrospinal fluid. Meningeal Neoplasms / cerebrospinal fluid
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. B-Lymphocytes / pathology. Female. Humans. Leukocytes / pathology. Male. Middle Aged. Sensitivity and Specificity. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19224854.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Rodríguez-Otero P; Pérez-Ceballos E; Monteserin MC; Diaz-Arias J; Pérez M; Domingo-Domenech E; Poderós C; Provencio M; Vallejo C; Forés R; Gómez E; de la Cruz M; Palacios A; Fernández S; Marin M; Hernández JA; Molero T; Romero-Picos E; Mateos MC; Peñarrubia M; Caballero D; Conde E
  •  go-up   go-down


26. Olivieri A, Santini G, Patti C, Chisesi T, De Souza C, Rubagotti A, Aversa S, Billio A, Porcellini A, Candela M, Centurioni R, Congiu AM, Brunori M, Nati S, Spriano M, Vimercati R, Marino G, Contu A, Tedeschi L, Majolino I, Crugnola M, Sertoli MR, NHLCSG: Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG. Ann Oncol; 2005 Dec;16(12):1941-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG.
  • BACKGROUND: There is not univocal concordance for using high-dose sequential therapy (HDS) as first-line treatment for aggressive non-Hodgkin's lymphoma (NHL).
  • We designed this study to evaluate the usefulness of HDS followed by high-dose therapy (HDT) with autologous stem cell transplantation as front-line treatment in different subsets of aggressive NHL.
  • PATIENTS AND METHODS: Among 223 patients aged 15-60 years with aggressive, advanced stage NHL, 106 patients were randomized to VACOP-B (etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin) for 12 weeks (plus HDS/HDT in case of persistent disease) (arm A), and 117 patients to VACOP-B for 8 weeks plus upfront HDS/HDT (arm B).
  • CONCLUSIONS: Aggressive NHL patients do not benefit from upfront HDS/HDT.

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16157621.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


27. Fridrik MA, Hausmaninger H, Lang A, Drach J, Krieger O, Geissler D, Michlmayr G, Ulsperger E, Chott A, Oberaigner W, Greil R: Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma. Ann Hematol; 2010 Mar;89(3):273-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma.
  • This study aimed to determine whether dose-dense therapy improves 3-year survival over the standard therapy for untreated aggressive lymphoma.
  • One hundred and fifteen patients with untreated aggressive lymphoma were stratified by center, age, and international prognostic index and randomized to one of two treatment arms.
  • Dose-dense therapy with CEOP/IMVP-Dexa is feasible and resulted in an absolute increase of 34% in the survival probability compared to CHOP in untreated patients with aggressive lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide. Dexamethasone. Doxorubicin. Epirubicin. Etoposide. Female. Filgrastim. Granulocyte Colony-Stimulating Factor. Humans. Ifosfamide. Infection / chemically induced. Male. Methotrexate. Middle Aged. Prednisolone. Prognosis. Recombinant Proteins. Survival Rate. Vincristine. Young Adult

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19693500.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00517894
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; PVI5M0M1GW / Filgrastim; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


28. Planinc-Peraica A, Kolonić SO, Radić-Kristo D, Dominis M, Jaksić B: Serum immunoglobulins in non-Hodgkin's lymphoma patients. Coll Antropol; 2010 Jun;34(2):407-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum immunoglobulins in non-Hodgkin's lymphoma patients.
  • Serum proteins and immunoglobulin (Ig) findings in 119 non-Hodgkin's lymphoma (NHL) patients were analysed.
  • Out of them 96 (81%) patients had B non-Hodgkin lymphoma (B-NHL), and 23 (19%) T-NHL.
  • Indolent type of NHL was more frequent (77 patients, 65%), then aggressive type of NHL (42 patients, 35%).
  • The statistically significant association was not found between serum Ig concentration and lymphoma malignancy grade as well as between serum Ig concentration and immunologic origin of lymphoma.
  • [MeSH-major] Immunoglobulins / blood. Lymphoma, Non-Hodgkin / immunology
  • [MeSH-minor] Adult. Blood Proteins / analysis. Humans. Immunoglobulin A / blood. Immunoglobulin G / blood. Immunoglobulin M / blood. Retrospective Studies. Serum Albumin / metabolism. Serum Globulins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698110.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Immunoglobulins; 0 / Serum Albumin; 0 / Serum Globulins
  •  go-up   go-down


29. Ziepert M, Schmits R, Trümper L, Pfreundschuh M, Loeffler M, German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL): Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma. Ann Oncol; 2008 Apr;19(4):752-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma.
  • PATIENTS AND METHODS: We analyzed data of 1399 patients with aggressive lymphoma from trials using CHOP (combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone)-like therapies.

  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18048382.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


30. Vranovsky A, Ladicka M, Lakota J: Autologous stem cell transplantation in first-line treatment of high-risk aggressive non-Hodgkin's lymphoma. Neoplasma; 2008;55(2):107-12
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation in first-line treatment of high-risk aggressive non-Hodgkin's lymphoma.
  • A single center, retrospective analysis evaluating the outcome of patients with poor-risk aggressive non-Hodgkin's lymphoma (NHL) treated with high-dose chemotherapy and autologous stem cell transplantation (ASCT) as a part of firstline therapy.
  • Forty-seven patients younger than 65 years with diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), peripheral T-cell lymphoma (PTCL) or alk-negative anaplastic large cell lymphoma (ALCL) underwent ASCT between July 1997 and November 2005.
  • Our results confirm the efficacy of high-dose therapy with ASCT during first-line treatment of patients with poor-prognosis aggressive lymphoma, with substantial number of patients cured by using this treatment approach.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Male. Methotrexate / therapeutic use. Middle Aged. Prednisolone / therapeutic use. Retrospective Studies. Transplantation, Autologous. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18652043.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; DHAP protocol; MACOP-B regimen
  •  go-up   go-down


31. Hohaus S, Giachelia M, Massini G, Mansueto G, Vannata B, Bozzoli V, Criscuolo M, D'Alò F, Martini M, Larocca LM, Voso MT, Leone G: Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. Ann Oncol; 2009 Aug;20(8):1408-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas.
  • PATIENTS AND METHODS: Cell-free DNA levels in the plasma samples of 142 patients with lymphomas [45 with Hodgkin's lymphoma (HL), 63 with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL), 24 with follicular, and 10 with mantle cell non-Hodgkin's lymphoma (NHL)] at diagnosis and of 41 healthy individuals were determined using a quantitative PCR for the beta-globin gene.
  • CONCLUSION: Quantification of circulating DNA by real-time PCR at diagnosis can identify patients with elevated levels that are associated with disease characteristics indicating aggressive disease and poor prognosis.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19465421.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / beta-Globins
  •  go-up   go-down


32. Moser EC, Noordijk EM, Carde P, Tirelli U, Baars JW, Thomas J, Bron D, Meerwaldt JH, van Glabbeke M, Raemaekers JM, Kluin-Nelemans HC: Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials. Clin Lymphoma Myeloma; 2005 Sep;6(2):122-30
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials.
  • BACKGROUND: A significant proportion of patients with aggressive non-Hodgkin's lymphoma (NHL) become long-term survivors.
  • A European Organisation for Research and Treatment of Cancer database of patients with aggressive NHL, consistently treated with doxorubicin-based chemotherapy since 1980, afforded the possibility to explore late complications in this patient group.
  • RESULTS: Late non-neoplastic events were found in 46% of the 757 patients.
  • CONCLUSION: Altogether, almost half the patients with aggressive NHL experienced events addressed as late non-neoplastic complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Lymphoma, Non-Hodgkin / complications. Salvage Therapy / adverse effects. Stem Cell Transplantation / adverse effects. Transplantation Conditioning / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Europe. Female. Follow-Up Studies. Humans. Male. Mechlorethamine / adverse effects. Mechlorethamine / therapeutic use. Middle Aged. Prednisone / adverse effects. Prednisone / therapeutic use. Procarbazine / adverse effects. Procarbazine / therapeutic use. Radiotherapy / adverse effects. Risk Factors. Smoking / adverse effects. Societies, Medical. Transplantation, Autologous. Vincristine / adverse effects. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16231850.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; VB0R961HZT / Prednisone; MOPP protocol
  •  go-up   go-down


33. Alici S, Bavbek S, Basaran M, Onat H: Prognostic factors in patients with aggressive non-Hodgkin's lymphoma without complete response to first-line therapy. Adv Ther; 2006 Jul-Aug;23(4):534-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in patients with aggressive non-Hodgkin's lymphoma without complete response to first-line therapy.
  • This study was conducted to retrospectively identify the prognostic factors that specifically predict survival rates of patients with aggressive non-Hodgkin's lymphoma who did not achieve a complete response (CR) to first-line therapy.
  • Prognostic factors in terms of survival were analyzed in 76 adult patients with non-Hodgkin's lymphoma who had failed to achieve CR to first-line chemotherapy (CT) regimens administered at Istanbul University, Institute of Oncology, between February 1989 and October 1998.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17050496.001).
  • [ISSN] 0741-238X
  • [Journal-full-title] Advances in therapy
  • [ISO-abbreviation] Adv Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Widmann TA, Herrmann M, Taha N, König J, Pfreundschuh M: Short telomeres in aggressive non-Hodgkin's lymphoma as a risk factor in lymphomagenesis. Exp Hematol; 2007 Jun;35(6):939-46
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short telomeres in aggressive non-Hodgkin's lymphoma as a risk factor in lymphomagenesis.
  • METHODS: We designed an (age-) matched pair analysis that compared telomere length in nonmalignant peripheral leukocytes from previously untreated patients who recently developed an aggressive non-Hodgkin's lymphoma, with leukocytes from healthy individuals.
  • [MeSH-major] Cell Transformation, Neoplastic / metabolism. Chromosomes, Human / metabolism. Lymphoma, Non-Hodgkin / metabolism. Telomere / metabolism
  • [MeSH-minor] Adult. B-Lymphocytes / metabolism. B-Lymphocytes / pathology. Female. Granulocytes / metabolism. Granulocytes / pathology. Humans. Male. Oxidative Stress / genetics. Risk Factors. T-Lymphocytes / metabolism. T-Lymphocytes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17533048.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


35. Moser EC, Noordijk EM, van Leeuwen FE, Baars JW, Thomas J, Carde P, Meerwaldt JH, van Glabbeke M, Kluin-Nelemans HC: Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study. Haematologica; 2006 Nov;91(11):1481-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study.
  • BACKGROUND AND OBJECTIVES: Second cancer has been associated with non-Hodgkin's Lymphoma (NHL) treatment, but few studies have addressed this issue considering specific treatments.
  • DESIGN AND METHODS: We estimated risk by standardized incidence ratios (SIR) and absolute excess risk (AER) based on general population rates (European Network of Cancer Registries) in 748 patients (aged 15-82 years) treated for aggressive NHL in four successive EORTC (European Organization for Research on Treatment of Cancer) trials.
  • Cancer risk appeared age-related: in young patients high risks were observed for leukemia (SIR 16.7,95% CI 1.4-93.1,AER 5.0), Hodgkin's lymphoma (SIR 60.1,95% CI 12.4-175.2, AER 15.7), colorectal cancer (SIR 12.5, 95% CI 2.6-36.5, AER 14.7) and lung cancer (SIR 15.4; 95% CI 4.2-39.4, AER 19.8), while risk in patients older than 45 years matched than that in the normal population.
  • INTERPRETATION AND CONCLUSIONS: Half of the patients die of aggressive NHL before living long enough to experience second cancer.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / epidemiology. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cohort Studies. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Europe / epidemiology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prednisone / adverse effects. Prednisone / therapeutic use. Registries. Retrospective Studies. Risk Factors. Vincristine / adverse effects. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17043014.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


36. Bernatsky S, Ramsey-Goldman R, Rajan R, Boivin JF, Joseph L, Lachance S, Cournoyer D, Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin PR, Edworthy S, Barr S, Gordon C, Bae SC, Sibley J, Steinsson K, Nived O, Sturfelt G, St Pierre Y, Clarke A: Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis; 2005 Oct;64(10):1507-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma in systemic lupus erythematosus.
  • BACKGROUND: Recent evidence supports an association between systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma (NHL).
  • In the patients, aggressive histological subtypes appeared to predominate, with the most commonly identified NHL subtype being diffuse large B cell (11 out of 21 cases for which histological subtype was available).
  • Twenty two of the patients had died a median of 1.2 years after lymphoma diagnosis.
  • CONCLUSIONS: These data suggest aggressive disease in patients with SLE who develop NHL.

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • MedlinePlus Health Information. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16162903.001).
  • [ISSN] 0003-4967
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / AR 02138; United States / NIAMS NIH HHS / AR / AR 48098
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1755239
  •  go-up   go-down


37. Intragumtornchai T, Bunworasate U, Nakorn TN, Rojnuckarin P: Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma. Leuk Lymphoma; 2006 Jul;47(7):1306-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
  • With currently available combination chemotherapy regimens, the outcome of the patients newly diagnosed with aggressive non-Hodgkin's lymphoma (NHL) identified as 'high' and 'high-intermediate' risk groups according to the international prognostic index (IPI) is still unsatisfactory and a more innovative therapy is urgently required to improve the survival of the patients.
  • The purpose of this study was to compare the efficacy of rituximab given in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and ESHAP (etoposide, methylprednisolone, high-dose Ara-C, cisplatin) vs CHOP-ESHAP and upfront high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) vs standard CHOP in patients aged < or = 65 years old newly diagnosed with 'high' and 'high-intermediate' risk aggressive lymphoma enrolled onto two consecutive treatment trials at the institute.
  • Between May 1995 - July 2002, 84 patients, aged 15 - 65 years old, with newly diagnosed aggressive NHL and an age-adjusted IPI of 2 or 3 were enrolled.
  • It is concluded that rituximab-ESHAP-CHOP is superior over standard CHOP and fares comparably to upfront HDT/ASCT in previously untreated patients with aggressive lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Methylprednisolone / administration & dosage. Middle Aged. Prednisone / administration & dosage. Proportional Hazards Models. Rituximab. Time Factors. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923561.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; VB0R961HZT / Prednisone; X4W7ZR7023 / Methylprednisolone; CHOP protocol; ESAP protocol
  •  go-up   go-down


38. Fabre-Guillevin E, Tabrizi R, Coulon V, Monnereau A, Eghbali H, Soubeyran I, Soubeyran P: Aggressive non-Hodgkin's lymphoma: concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome. Leuk Lymphoma; 2006 Apr;47(4):603-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive non-Hodgkin's lymphoma: concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome.
  • The purpose of this study was to assess the prognostic value of a large panel of cytokines in aggressive non-Hodgkin's lymphoma (NHL) and to confront it to parameters of the International Prognostic Index (IPI).
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Interleukin-10 / biosynthesis. Interleukin-2 / biosynthesis. Interleukin-4 / biosynthesis. Interleukin-6 / biosynthesis. Lymphoma, Non-Hodgkin / metabolism. Lymphoma, Non-Hodgkin / therapy. Receptors, Interleukin-2 / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Apr;47(4):570-2 [16886266.001]
  • (PMID = 16690518.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interleukin-2; 0 / Interleukin-6; 0 / Receptors, Interleukin-2; 130068-27-8 / Interleukin-10; 207137-56-2 / Interleukin-4
  •  go-up   go-down


39. Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, Sehn LH, Shenkier TN, Gascoyne RD, Connors JM: Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol; 2008 Nov 10;26(32):5165-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma.
  • PURPOSE: To assess the incidence and predictive factors for development of transformed lymphoma in a population-based series of patients with follicular lymphoma (FL).
  • Transformed lymphoma was defined as the development of aggressive non-Hodgkin's lymphoma (NHL) in patients with FL.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Lymphoma, Follicular / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Biopsy. British Columbia / epidemiology. Disease Progression. Female. Humans. Incidence. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Population Surveillance. Registries. Retrospective Studies. Risk Assessment. Risk Factors. Time Factors. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18838711.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


40. Kube D, Hua TD, von Bonin F, Schoof N, Zeynalova S, Klöss M, Gocht D, Potthoff B, Tzvetkov M, Brockmöller J, Löffler M, Pfreundschuh M, Trümper L: Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study. Clin Cancer Res; 2008 Jun 15;14(12):3777-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study.
  • PURPOSE: Current chemotherapy can achieve high response rates in aggressive non-Hodgkin's lymphoma (NHL), but the factors that influence regression and survival remain unknown.
  • EXPERIMENTAL DESIGN: Five hundred patients with aggressive NHL treated with CHOP/CHOEP were analyzed for IL-10 gene polymorphisms, including distal loci -7400InDel, -6752AT (rs6676671), and -6208CG (rs10494879) in comparison with proximal loci -3538AT (rs1800890), -1087AG (rs1800896), and -597AC (rs1800872) according to the incidence and outcome of the lymphoma.
  • RESULTS: No differences in allele frequencies or haplotypes were found comparing a cohort of patients with aggressive NHL/diffuse large B-cell lymphoma with a healthy control group.
  • Patients with aggressive NHL characterized by IL-10(-7400DelDel) had shorter overall survival periods compared with the other genotypes (P = 0.004).
  • No associations were found analyzing diffuse large B-cell lymphoma patients separately.
  • CONCLUSION: Our results indicate that IL-10 gene variations could be associated to the clinical course of aggressive NHL, which points out the importance of host factors and respective genetic elements for treatment response.
  • [MeSH-major] Interleukin-10 / genetics. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Female. Gene Frequency. Genotype. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18559596.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 130068-27-8 / Interleukin-10
  •  go-up   go-down


41. Bairey O, Blickstein D, Monselise Y, Lahav J, Stark P, Prokocimer M, Nativ HM, Kirgner I, Pazgal I, Shaklai M: Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma. Eur J Haematol; 2006 May;76(5):384-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma.
  • The aim of this study was to determine the prevalence of IgG, IgM, and IgA anticardiolipin antibodies (aCL) and anti-beta-2 glycoprotein I antibodies (anti-beta2-GPI) in patients with non-Hodgkin's lymphoma (NHL), and to investigate their clinical and prognostic significance.
  • Their level may serve as an independent prognostic variable in aggressive NHL.
  • [MeSH-major] Antibodies, Antiphospholipid / blood. Autoantibodies / blood. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Anticardiolipin / blood. Enzyme-Linked Immunosorbent Assay. Female. Follow-Up Studies. Glycoproteins / immunology. Humans. Lupus Coagulation Inhibitor / blood. Male. Middle Aged. Partial Thromboplastin Time. Prognosis. Retrospective Studies. Sensitivity and Specificity. Survival Rate. Treatment Outcome. beta 2-Glycoprotein I

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16466368.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Anticardiolipin; 0 / Antibodies, Antiphospholipid; 0 / Autoantibodies; 0 / Glycoproteins; 0 / Lupus Coagulation Inhibitor; 0 / beta 2-Glycoprotein I
  •  go-up   go-down


42. Zhai L, Guo C, Cao Y, Xiao J, Fu X, Huang J, Huang H, Guan Z, Lin T: Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin's lymphoma: single center, 15-year experience. Int J Hematol; 2010 Jan;91(1):78-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin's lymphoma: single center, 15-year experience.
  • Few studies have compared the long-term outcomes of patients receiving pirarubicin-based THP-COP and doxorubicin-based CHOP in the treatment of non-Hodgkin's lymphoma (NHL).
  • We retrospectively compared the efficacy and safety of these two regimens in 459 previously untreated aggressive NHL patients admitted to Sun Yat-Sen University Cancer Center from 1987 to 2003.
  • At a median follow-up of 95.7 months, the 8-year survival rates were also similar (overall survival: THP-COP, 55.8% vs. CHOP, 56.7%; progression-free survival: THP-COP, 47.3% vs. CHOP, 43.5%; lymphoma-specific survival: THP-COP, 51.2% vs. CHOP, 48.5%).
  • In combination chemotherapy for aggressive NHL, pirarubicin has comparable efficacy to doxorubicin and has a lower incidence of alopecia, gastrointestinal toxicities, and arrhythmia.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Doxorubicin / analogs & derivatives. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / adverse effects. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects. Young Adult

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cancer Res Clin Oncol. 2004 Feb;130(2):107-13 [14648210.001]
  • [Cites] Int J Mol Med. 1998 Feb;1(2):491-4 [9852255.001]
  • [Cites] Hematol Oncol. 2007 Sep;25(3):107-14 [17457949.001]
  • [Cites] Int J Hematol. 2005 Apr;81(3):246-54 [15814336.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Ann Intern Med. 1979 Nov;91(5):710-7 [496103.001]
  • [Cites] Blood. 2004 Aug 1;104(3):634-41 [15016643.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2007 May;29(5):391-5 [17892140.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):602-11 [11157009.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;23(5):311-5 [2706737.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] Eur J Cancer. 1992;28A(10):1670-6 [1389483.001]
  • [Cites] Gan To Kagaku Ryoho. 1997 Jan;24(1):61-6 [9020947.001]
  • [Cites] J Antibiot (Tokyo). 1979 Oct;32(10):1082-4 [528373.001]
  • [Cites] Leukemia. 1997 Nov;11(11):1817-20 [9369412.001]
  • [Cites] Pediatr Res. 2002 Feb;51(2):256-9 [11809923.001]
  • [Cites] Gan To Kagaku Ryoho. 1984 Jan;11(1):138-42 [6696455.001]
  • [Cites] J Antibiot (Tokyo). 1979 Oct;32(10):1085-6 [528374.001]
  • [Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] Oncology. 1990;47(1):25-8 [2300381.001]
  • [Cites] Hematol J. 2000;1(1):53-66 [11920170.001]
  • [Cites] Cancer. 1997 Dec 15;80(12):2311-20 [9404709.001]
  • [Cites] Tsitologiia. 1997;39(10):928-37 [9505340.001]
  • [Cites] Rinsho Ketsueki. 1993 Dec;34(12):1532-9 [8295326.001]
  • [Cites] Ann Oncol. 1992 May;3(5):379-86 [1616892.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):847-52 [15465202.001]
  • [Cites] Zhonghua Xue Ye Xue Za Zhi. 2005 Oct;26(10):577-80 [16532963.001]
  • [Cites] Biomed Pharmacother. 1986;40(10):376-9 [3580506.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Ann Oncol. 1996 Nov;7(9):966-9 [9006749.001]
  • [Cites] Am J Clin Oncol. 1990;13 Suppl 1:S15-9 [2291455.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] Radiat Med. 2005 May;23(3):156-61 [15940061.001]
  • (PMID = 20033628.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; D58G680W0G / pirarubicin; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


43. Bonnet C, Beguin Y, Fassotte MF, Seidel L, Luyckx F, Fillet G: Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma. Eur J Haematol; 2007 May;78(5):399-404
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
  • BACKGROUND: Several papers have reported an association of high CA125 serum levels with advanced non-Hodgkin's lymphoma (NHL) as well as a relationship between high CA125 values and poor outcome.
  • PATIENTS AND METHODS: Ninety-nine patients with NHL or Hodgkin's disease (HD) underwent serum CA125 assessment at diagnosis.
  • RESULTS: CA125 serum levels were elevated in 34% of the patients, including 19% of patients with aggressive NHL, 45% of patients with indolent NHL, and 29% of patients with HD.
  • CONCLUSION: While CA125 serum level correlates significantly with a number of features associated with more aggressive disease, it does not enhance the performance of standard prognostic markers in the management of patients with NHL or HD.
  • [MeSH-major] CA-125 Antigen / blood. Hodgkin Disease / blood. Lymphoma, Non-Hodgkin / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multivariate Analysis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419741.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


44. Juweid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE, Mottaghy FM, Rohren EM, Blumstein NM, Stolpen A, Link BK, Reske SN, Graham MM, Cheson BD: Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol; 2005 Jul 20;23(21):4652-61
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.
  • PURPOSE: To determine whether a response classification based on integration of fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET) into the International Workshop Criteria (IWC) provides a more accurate response assessment than IWC alone in patients with non-Hodgkin's lymphoma (NHL).
  • PATIENTS AND METHODS: Fifty-four patients with aggressive NHL who underwent FDG-PET and computed tomography 1 to 16 weeks after four to eight cycles of chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone were assessed for complete response (CR), unconfirmed CR (CRu), partial response (PR), stable disease (SD), and progressive disease (PD) by the IWC and by integrated IWC and FDG-PET (IWC+PET).
  • CONCLUSION: Compared with IWC, the IWC+PET-based assessment provides a more accurate response classification in patients with aggressive NHL.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Humans. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837965.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA972784
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


45. Aboud A, Marx G, Sayer H, Gummert JF: Successful treatment of an aggressive non-Hodgkin's lymphoma associated with acute respiratory insufficiency using extracorporeal membrane oxygenation. Interact Cardiovasc Thorac Surg; 2008 Feb;7(1):173-4
MedlinePlus Health Information. consumer health - Respiratory Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of an aggressive non-Hodgkin's lymphoma associated with acute respiratory insufficiency using extracorporeal membrane oxygenation.
  • Non-Hodgkin's lymphoma initially presenting as a solid huge mediastinal mass does not frequently occur.
  • Although nowadays many patients with high-grade (aggressive) malignant lymphoma can be cured using a combination of immuno- and chemotherapy, rapid progression and acute complications caused by the tumor mass itself may necessitate additional invasive treatment.
  • We report a case of successful extracorporeal membrane oxygenation treatment in a 43-year-old woman with acute respiratory insufficiency due to a huge mediastinal non-Hodgkin's tumor.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Extracorporeal Membrane Oxygenation / methods. Immunosuppressive Agents / therapeutic use. Lymphoma, Non-Hodgkin / therapy. Mediastinal Neoplasms / therapy. Respiratory Insufficiency / therapy
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Respiratory Function Tests

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18045830.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents
  •  go-up   go-down


46. Han HS, Escalón MP, Hsiao B, Serafini A, Lossos IS: High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. Ann Oncol; 2009 Feb;20(2):309-18
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens.
  • BACKGROUND: Positron emission tomography (PET) is a powerful predictor of relapse and survival in non-Hodgkin's lymphomas (NHLs) based on studies carried out in the prerituximab era.
  • PATIENTS AND METHODS: Patients with aggressive B-cell NHL with baseline and follow-up PET studies were included.
  • RESULTS: In all, 51 patients (diffuse large B cell-38; mantle cell lymphoma-13) treated with rituximab-containing regimens were included.
  • CONCLUSIONS: Compared with previous reports in prerituximab era, addition of rituximab resulted in reduced PPV and sensitivity of mid- and posttherapy PET in patients with aggressive B-cell NHL.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 Aug 15;106(4):1376-81 [15860666.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4652-61 [15837965.001]
  • [Cites] Ann Oncol. 2005 Sep;16(9):1514-23 [15980161.001]
  • [Cites] Ann Hematol. 2006 Nov;85(11):759-67 [16871391.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Haematologica. 2000 Jun;85(6):613-8 [10870118.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):414-9 [11208833.001]
  • [Cites] Leuk Lymphoma. 2000 Nov;39(5-6):543-53 [11342337.001]
  • [Cites] J Nucl Med. 2002 Aug;43(8):1018-27 [12163626.001]
  • [Cites] Ann Oncol. 2002 Sep;13(9):1356-63 [12196360.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 May;30(5):682-8 [12601498.001]
  • [Cites] Acta Med Austriaca. 2003;30(2):41-7 [12752087.001]
  • [Cites] Br J Cancer. 2004 Aug 31;91(5):850-4 [15266320.001]
  • [Cites] Blood. 1999 Jul 15;94(2):429-33 [10397709.001]
  • [Cites] Ann Oncol. 2005 Sep;16(9):1524-9 [15946979.001]
  • (PMID = 18842613.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109335; United States / NCI NIH HHS / CA / R01 CA122105
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  • [Other-IDs] NLM/ PMC2733066
  •  go-up   go-down


47. Sotnikov VM, Pan'shin GA, Datsenko PV, Ivashin AV, Smol'tsova NN: [The role of adjuvant radiotherapy in the complex treatment of stage III-IV aggressive non-Hodgkin's lymphoma]. Vopr Onkol; 2009;55(4):443-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of adjuvant radiotherapy in the complex treatment of stage III-IV aggressive non-Hodgkin's lymphoma].
  • Immediate and end results of chemoradiotherapy of 225 patients (average age--43 years) with primary aggressive non-Hodgkin's lymphomas stage III-IV were evaluated.
  • The disease is specific, so relapse-free survival in cases of generalized primary aggressive lymphoma in full remission remained unchanged too whatever the stage at which full remission emerged.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19947367.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


48. Robertson MJ, Abonour R, Hromas R, Nelson RP, Fineberg NS, Cornetta K: Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma. Leuk Lymphoma; 2005 Oct;46(10):1477-87
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma.
  • Progressive disease is the major cause of treatment failure after autologous hematopoietic stem cell transplantation for relapsed or refractory non-Hodgkin's lymphoma.
  • Sixty-seven adult patients received augmented CBV followed by infusion of unpurged autologous peripheral blood stem cells.
  • Thirty seven patients had relapsed after standard chemotherapy, 28 patients had primary refractory disease, and 2 patients had transformed lymphoma in first partial response.
  • Risk factors for disease progression were histologic involvement of marrow by lymphoma and infusion of increased numbers of CD34 + cells per kg in the stem cell autograft.
  • [MeSH-major] Carmustine / therapeutic use. Cyclophosphamide / therapeutic use. Etoposide / therapeutic use. Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / surgery
  • [MeSH-minor] Adult. Aged. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Survival Rate. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194894.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR00750-310649; United States / NCRR NIH HHS / RR / M01 RR00750-310698; United States / NCRR NIH HHS / RR / M01 RR750
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; U68WG3173Y / Carmustine
  •  go-up   go-down


49. Tulpule A, Espina BM, Berman N, Buchanan LH, Smith DL, Sherrod A, Dharmapala D, Gee C, Boswell WD, Nathwani BN, Welles L, Levine AM: Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. Clin Lymphoma Myeloma; 2006 Jul;7(1):59-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma.
  • BACKGROUND: The toxicity and efficacy of nonpegylated liposomal doxorubicin (TLC D-99) when substituted for conventional doxorubicin in the CHOP (doxorubicin/cyclophosphamide/vincristine/prednisone) regimen were evaluated in the treatment of newly diagnosed patients with aggressive non-Hodgkin's lymphoma.
  • Immunohistochemistry for MDR-1-related p-glycoprotein was assessed in lymphoma tissues from 27 patients.
  • Of the 27 lymphoma tissues studied, 8 (30%) were MDR-1 positive at diagnosis.
  • CONCLUSION: Nonpegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, and prednisone is an active regimen for patients with newly diagnosed, aggressive non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Prednisone / administration & dosage. Vincristine / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Remission Induction. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879771.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


50. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P, Couriel D, De Lima M, Donato ML, Fayad L, Giralt S, Jones R, Korbling M, Maadani F, Manning JT, Pro B, Shpall E, Younes A, McLaughlin P, Champlin RE: Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol; 2005 Apr 1;23(10):2240-7
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.
  • PURPOSE: We investigated the efficacy and safety of administering high-dose rituximab (HD-R) in combination with high-dose carmustine, cytarabine, etoposide, and melphalan chemotherapy and autologous stem-cell transplantation (SCT) in patients with recurrent B-cell aggressive non-Hodgkin's lymphoma (NHL).
  • CONCLUSION: The results of this study suggest that using HD-R and autologous SCT is a feasible and promising treatment for patients with B-cell aggressive NHL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Carmustine / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Infusions, Intravenous. Injections, Subcutaneous. Male. Melphalan / administration & dosage. Middle Aged. Rituximab. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800314.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 6PLQ3CP4P3 / Etoposide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine
  •  go-up   go-down


51. Fan Y, Huang ZY, Luo LH, Yu HF: [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases]. Ai Zheng; 2008 Nov;27(11):1222-5
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
  • BACKGROUND & OBJECTIVE: The prognosis of relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) after front-line therapy remains poor.
  • Gemcitabine is effective in treating lymphoma and, when combined with cisplatin, is effective for some solid tumors.
  • This study was to evaluate the efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive NHL, and observe the adverse events.
  • METHODS: Patients with relapsed or refractory aggressive NHL, measurable disease, and had received previously at least one chemotherapy regimen were enrolled and treated with GDP regimen (gemcitabine 1000 mg/m2 on Days 1 and 8, dexamethasone 20-40 mg on Days 1-3, and cisplatin 25 mg/m2 on Days 1-3) every 3 weeks.
  • Non-hematologic toxicities were mild.
  • CONCLUSION: GDP regimen is an effective and relatively nontoxic salvage chemotherapy regimen for relapsed or refractory aggressive NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / adverse effects. Cisplatin / therapeutic use. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Dexamethasone / adverse effects. Dexamethasone / therapeutic use. Female. Humans. Leukopenia / chemically induced. Male. Middle Aged. Neoplasm Recurrence, Local. Remission Induction. Salvage Therapy. Stem Cell Transplantation. Survival Rate. Thrombocytopenia / chemically induced. Young Adult

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19000458.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin; GDP protocol
  •  go-up   go-down


52. Bellizzi KM, Rowland JH, Arora NK, Hamilton AS, Miller MF, Aziz NM: Physical activity and quality of life in adult survivors of non-Hodgkin's lymphoma. J Clin Oncol; 2009 Feb 20;27(6):960-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physical activity and quality of life in adult survivors of non-Hodgkin's lymphoma.
  • PURPOSE: To examine the prevalence and correlates of physical activity in adult survivors of aggressive non-Hodgkin's Lymphoma (NHL) and to explore the association between physical activity level and health-related quality of life (HRQOL).

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Sci Sports Exerc. 2000 Jan;32(1):149-56 [10647542.001]
  • [Cites] Compr Ther. 1997 Sep;23(9):605-11 [9285161.001]
  • [Cites] Psychooncology. 2000 Mar-Apr;9(2):127-36 [10767750.001]
  • [Cites] Ann Behav Med. 2001 Fall;23(4):229-46 [11761340.001]
  • [Cites] Semin Oncol Nurs. 2001 Nov;17(4):241-8 [11764707.001]
  • [Cites] Med Oncol. 2001;18(1):85-94 [11778974.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1660-8 [12721239.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3390-4 [9345021.001]
  • [Cites] Cancer Nurs. 1997 Dec;20(6):430-9 [9409065.001]
  • [Cites] Oncol Nurs Forum. 1998 Jan-Feb;25(1):107-13 [9460778.001]
  • [Cites] Semin Oncol Nurs. 1998 Nov;14(4):321-8 [9839345.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3577-87 [15908668.001]
  • [Cites] JAMA. 2005 May 25;293(20):2479-86 [15914748.001]
  • [Cites] Oncology (Williston Park). 2005 Apr;19(4 Suppl 1):26-34 [15934515.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1588-95 [16030088.001]
  • [Cites] J Med Libr Assoc. 2005 Jul;93(3):353-62 [16059425.001]
  • [Cites] Psychooncology. 2005 Nov;14(11):979-91 [15744764.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8884-93 [16314649.001]
  • [Cites] CMAJ. 2006 Jul 4;175(1):34-41 [16818906.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3527-34 [16822844.001]
  • [Cites] Support Care Cancer. 2006 Oct;14(10):1012-9 [16538497.001]
  • [Cites] Nurs Res. 2007 Jan-Feb;56(1):18-27 [17179870.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jan;101(2):225-32 [17028988.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):566-71 [17372253.001]
  • [Cites] J Aging Phys Act. 2007 Jan;15(1):103-18 [17387232.001]
  • [Cites] Acta Oncol. 2007;46(4):417-32 [17497308.001]
  • [Cites] Gynecol Oncol. 2007 Jul;106(1):244-50 [17493671.001]
  • [Cites] Ann Behav Med. 2007 Oct;34(2):188-99 [17927557.001]
  • [Cites] J Cancer Surviv. 2007 Mar;1(1):49-63 [18648945.001]
  • [Cites] Med Sci Sports Exerc. 2003 Nov;35(11):1846-52 [14600549.001]
  • [Cites] Med Sci Sports Exerc. 2004 Feb;36(2):253-60 [14767248.001]
  • [Cites] J Clin Epidemiol. 2004 Jun;57(6):571-9 [15246125.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Sep;51(3):249-61 [15331082.001]
  • [Cites] Acta Psychiatr Scand. 1983 Jun;67(6):361-70 [6880820.001]
  • [Cites] Can J Appl Sport Sci. 1985 Sep;10(3):141-6 [4053261.001]
  • [Cites] J Pers Soc Psychol. 1987 Aug;53(2):273-9 [3625467.001]
  • [Cites] J Natl Cancer Inst. 1993 Jun 16;85(12):979-87 [8496983.001]
  • [Cites] Med Sci Sports Exerc. 1994 Jun;26(6):649-60 [8052103.001]
  • [Cites] J Natl Cancer Inst Monogr. 1994;(16):101-12 [7999452.001]
  • [Cites] JAMA. 1995 Feb 1;273(5):402-7 [7823386.001]
  • [Cites] Am J Epidemiol. 1995 Jul 15;142(2):191-201 [7598119.001]
  • [Cites] Health Educ Res. 1995 Mar;10(1):51-64 [10150421.001]
  • [Cites] Br J Soc Psychol. 1995 Jun;34 ( Pt 2):199-220 [7620846.001]
  • [Cites] Health Psychol. 2000 Mar;19(2):155-64 [10762099.001]
  • (PMID = 19139438.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / PHS HHS / / U55/CCR921930-02; United States / NCI NIH HHS / PC / N02-PC-15105; United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCI NIH HHS / PC / N02 PC015105; United States / NCI NIH HHS / CA / N01PC35139
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2668638
  •  go-up   go-down


53. Han LN, Zhou J, Hirose T, Imai Y, Ishiguro T, Chou T: Feasibility and efficacy of high-dose melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) chemotherapy with or without rituximab followed by autologous stem cell transplantation for aggressive and relapsed non-Hodgkin's lymphoma. Int J Hematol; 2006 Aug;84(2):174-81
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility and efficacy of high-dose melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) chemotherapy with or without rituximab followed by autologous stem cell transplantation for aggressive and relapsed non-Hodgkin's lymphoma.
  • To investigate the feasibility and efficacy of high-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) for patients with newly diagnosed aggressive and relapsed non-Hodgkin's lymphoma (NHL), we administered LEED, a drug-only HDCT regimen consisting of melphalan, cyclophosphamide, etoposide, and dexamethasone, followed by ASCT in this single-institution trial.
  • These results suggested that LEED, as well as R-LEED, was a safe and feasible high-dose regimen for aggressive and relapsed NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Melphalan / administration & dosage. Middle Aged. Recurrence. Rituximab. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Jul 15;102(2):749-55 [12663455.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4561-6 [15542807.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2153-64 [11304767.001]
  • [Cites] Int J Hematol. 2003 Jun;77(5):503-11 [12841390.001]
  • [Cites] Br J Haematol. 2002 Jan;116(1):229-35 [11841421.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1287-95 [15044639.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):3025-30 [10944137.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3793-801 [15809447.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] Clin Lymphoma. 2005 Jun;6(1):31-6 [15989704.001]
  • [Cites] Ann Oncol. 2003 Apr;14(4):520-35 [12649096.001]
  • [Cites] Blood. 2000 Aug 1;96(3):864-9 [10910898.001]
  • [Cites] Bone Marrow Transplant. 1997 Dec;20(11):953-9 [9422474.001]
  • [Cites] N Engl J Med. 1997 May 1;336(18):1290-7 [9113932.001]
  • [Cites] Bone Marrow Transplant. 2002 May;29(9):769-75 [12040475.001]
  • [Cites] Ann Hematol. 2002;81 Suppl 2:S54-5 [12611079.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):268-76 [10458242.001]
  • [Cites] Blood. 2004 May 15;103(10):3684-8 [14739217.001]
  • [Cites] Gan To Kagaku Ryoho. 2005 Dec;32(13):2059-64 [16352929.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2472-9 [12011124.001]
  • [Cites] Blood. 2004 Feb 1;103(3):777-83 [12907446.001]
  • [Cites] Bone Marrow Transplant. 2003 Jul;32(2):139-43 [12838277.001]
  • [Cites] Haematologica. 2000 Sep;85(9):943-51 [10980633.001]
  • [Cites] Bone Marrow Transplant. 1991 Oct;8(4):239-44 [1721856.001]
  • [Cites] Leuk Lymphoma. 2003 Jul;44(7):1151-8 [12916867.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2253-9 [15512814.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2165-70 [11304768.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 1:i21-7 [12736227.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Leuk Lymphoma. 2005 Nov;46(11):1569-73 [16236611.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1255-62 [12663712.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2240-7 [15800314.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1131-7 [9060555.001]
  • [Cites] Hematol J. 2003;4(2):110-5 [12750729.001]
  • (PMID = 16926142.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan
  •  go-up   go-down


54. Tsirigotis P, Dray L, Resnick IB, Ackerstein A, Gesundheit B, Elad S, Or R, Shapira MY: Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin's lymphoma. Ann Hematol; 2010 Mar;89(3):263-72
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin's lymphoma.
  • The major cause of treatment failure following high-dose therapy with autologous stem cell transplantation (ASCT) for aggressive B cell non-Hodgkin's lymphoma (NHL) is persistent disease or recurrence.
  • We describe our experience with the administration of rituximab post-ASCT, either as maintenance therapy or for the treatment of relapsed disease in patients with aggressive B cell NHL.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, B-Cell / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Remission Induction. Rituximab. Secondary Prevention. Survival Analysis. Transplantation, Autologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19693502.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


55. Lim ST, Fayad L, Tulpule A, Modiano M, Cabanillas F, Laffranchi B, Allievi C, Bernareggi A, Levine AM: A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. Leuk Lymphoma; 2007 Feb;48(2):374-80
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma.
  • The purpose of the study was to evaluate the safety, efficacy, and pharmacokinetics of pixantrone (BBR2778) when substituted for etoposide in the ESHAP regimen in patients with aggressive relapsed or refractory non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Follicular / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Female. Humans. Isoquinolines / administration & dosage. Male. Methylprednisolone / administration & dosage. Middle Aged. Prospective Studies. Remission Induction. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325899.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Isoquinolines; 04079A1RDZ / Cytarabine; F5SXN2KNMR / pixantrone; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


56. Pedersen LM, Klausen TW, Davidsen UH, Johnsen HE: Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma. Ann Hematol; 2005 Aug;84(8):510-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma.
  • Several lines of evidence suggest that serum levels of interleukin (IL)-6 and vascular endothelial growth factor (VEGF) are independent indicators of long-term outcome in non-Hodgkin's lymphoma (NHL), but the clinical impact of early serial monitoring of these cytokines has not been reported.
  • Serum samples from 64 newly diagnosed patients with aggressive NHL were obtained before the first cycle of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and then weekly until the second cycle was given.
  • [MeSH-major] Interleukin-6 / blood. Lymphoma, Non-Hodgkin / diagnosis. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Inflammation / blood. Male. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Prednisone / therapeutic use. Prognosis. Survival Analysis. Treatment Outcome. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15834569.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / Vascular Endothelial Growth Factor A; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


57. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Fisher RI: Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Leuk Lymphoma; 2005 Nov;46(11):1569-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
  • The present study aimed to determine the long-term safety and efficacy of chimeric anti-CD 20 antibody rituxan (rituximab, Biogen IDEC, San Diego, CA, USA; Genentech, South San Francisco, CA, USA) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy in previously untreated patients with aggressive non-Hodgkin's lymphoma (NHL).
  • Thirty-three patients with previously untreated aggressive B-cell NHL received six infusions of rituximab (375 mg/m(2) per dose) on day 1 of each cycle of CHOP chemotherapy, given on day 3 of each cycle of therapy.
  • The long-term follow-up of patients in this phase II trial of rituximab with CHOP chemotherapy for previously untreated aggressive NHL demonstrates a high response rate, which remains very durable with high 5-year overall and progression-free survivals.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Cause of Death. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality. Male. Middle Aged. Prednisone / administration & dosage. Remission Induction. Rituximab. Survival Analysis. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236611.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


58. Mihaljević B, Nedeljkov-Janćić R, Cemerikić-Martinović V, Babić D, Colović M: Ki-67 proliferative marker in lymph node aspirates of patients with non-Hodgkin's lymphoma. Med Oncol; 2006;23(1):83-89

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ki-67 proliferative marker in lymph node aspirates of patients with non-Hodgkin's lymphoma.
  • Proliferative activity of lymphoma cells was tested by immunocytochemical staining with Ki-67 monoclonal antibody in 63 aspirates of peripheral lymph nodes sampled from patients suffering from non-Hodgkin's lymphoma.
  • Referring to the dominant cell population in nodal aspirates, a rising trend of Ki-67 proliferative marker was noted from the small cells (X = 13.20) and small cells with notched nucleus (X = 43.52) and large cells (X = 79.47) with histopathologic equivalents corresponding to aggressive lymphoma.
  • Statistically significant correlation of Ki-67 with cytomorphology and REAL-immunocytochemical classification of lymphoma was confirmed, but not with the IPI index.
  • In order to determine the prognostic importance of Ki-67 marker, the patients were classified into those with low Ki-67 (<20% of proliferating cells), mean proliferation index Ki-67 (range 20-59%), and high proliferative index Ki-67 (positive in over 60% of lymphoma cells).
  • [MeSH-major] Ki-67 Antigen / analysis. Lymph Nodes / chemistry. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1460-6 [8123837.001]
  • [Cites] Diagn Cytopathol. 1995 May;12(3):234-8; discussion 238-40 [7621718.001]
  • [Cites] Pathol Res Pract. 2001;197(6):385-93 [11432665.001]
  • [Cites] Cancer. 2004 Jun 25;102(3):174-85 [15211477.001]
  • [Cites] J Clin Pathol. 1990 Apr;43(4):325-8 [2341568.001]
  • [Cites] Blood. 1988 Apr;71(4):1157-60 [3281723.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4085-9 [8943841.001]
  • [Cites] Cancer. 1988 Sep 1;62(5):989-93 [3409179.001]
  • [Cites] Am J Pathol. 1991 Apr;138(4):867-73 [2012175.001]
  • [Cites] Ann Hematol. 2004 Jul;83(7):414-9 [15085385.001]
  • [Cites] Acta Cytol. 2004 Mar-Apr;48(2):119-26 [15085740.001]
  • [Cites] Pathol Int. 2004 Sep;54(9):667-74 [15363034.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Jun;12(2):97-104 [15354733.001]
  • [Cites] Cytopathology. 2000 Oct;11(5):290-301 [11014656.001]
  • [Cites] Acta Oncol. 2002;41(1):36-43 [11990516.001]
  • [Cites] Med Oncol. 2001;18(1):15-22 [11778965.001]
  • [Cites] J Pathol. 1988 Mar;154(3):223-35 [2450981.001]
  • [Cites] Verh Dtsch Ges Pathol. 1992;76:117-21 [1283240.001]
  • [Cites] Cancer. 2003 Dec 25;99(6):385-93 [14681948.001]
  • [Cites] J Clin Pathol. 1998 Mar;51(3):189-96 [9659258.001]
  • [Cites] World J Gastroenterol. 2004 Jul 1;10(13):1862-6 [15222024.001]
  • [Cites] Hematol Oncol. 1984 Oct-Dec;2(4):365-71 [6396192.001]
  • (PMID = 16645233.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


59. Fagnoni P, Milpied N, Limat S, Deconinck E, Nerich V, Foussard C, Colombat P, Harousseau JL, Woronoff-Lemsi MC, Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang: Cost effectiveness of high-dose chemotherapy with autologous stem cell support as initial treatment of aggressive non-Hodgkin's lymphoma. Pharmacoeconomics; 2009;27(1):55-68
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost effectiveness of high-dose chemotherapy with autologous stem cell support as initial treatment of aggressive non-Hodgkin's lymphoma.
  • CHOP) in adults with aggressive non-Hodgkin's lymphoma (NHL).
  • The aim of the study was to evaluate the pharmacoeconomic profile of HDT with PBSCT support relative to standard CHOP therapy as first-line treatment in adults with aggressive NHL.
  • Uncertainty was assessed using non-parametric bootstrap simulations and various scenario analyses.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / economics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy / economics. Cost-Benefit Analysis. Lymphoma, Non-Hodgkin / economics. Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation / economics
  • [MeSH-minor] Adult. Cyclophosphamide / economics. Cyclophosphamide / therapeutic use. Doxorubicin / economics. Doxorubicin / therapeutic use. Female. Humans. Male. Prednisolone / economics. Prednisolone / therapeutic use. Randomized Controlled Trials as Topic. Time Factors. Transplantation, Autologous / economics. Vincristine / economics. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Value Health. 2005 Jul-Aug;8(4):462-70 [16091023.001]
  • [Cites] Rev Epidemiol Sante Publique. 2000 Jan;48(1):53-70 [10740085.001]
  • [Cites] Eur J Haematol. 2005 Aug;75(2):116-23 [16000127.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(14):1781-9 [11549432.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1287-95 [15044639.001]
  • [Cites] Ann Oncol. 2006 May;17 Suppl 4:iv8-11 [16702186.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):3025-30 [10944137.001]
  • [Cites] Health Econ. 1997 Jul-Aug;6(4):327-40 [9285227.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6387-93 [16155024.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):81-4 [10638970.001]
  • [Cites] Presse Med. 1992 Sep 12;21(29):1364-8 [1454765.001]
  • [Cites] Eur J Cancer. 2000 Dec;36(18):2360-7 [11094310.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] Bone Marrow Transplant. 2005 Jun;35(12):1149-53 [15880133.001]
  • [Cites] Haematologica. 2005 May;90(5):661-71 [15921381.001]
  • [Cites] Bone Marrow Transplant. 1997 Dec;20(11):975-82 [9422478.001]
  • [Cites] JAMA. 1997 Jun 11;277(22):1802-6 [9178794.001]
  • [Cites] Pharmacoeconomics. 2004;22(4):207-24 [14974872.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):5-10 [8996118.001]
  • [Cites] Health Policy. 1990 Dec;16(3):199-208 [10109801.001]
  • [Cites] N Engl J Med. 2006 Apr 27;354(17):1813-26 [16641398.001]
  • [Cites] Bone Marrow Transplant. 2000 May;25(9):997-1002 [10800070.001]
  • [Cites] Lancet. 2001 Oct 13;358(9289):1251-6 [11675082.001]
  • [Cites] Pharmacoeconomics. 1999 Mar;15(3):305-11 [10537437.001]
  • [Cites] Pharmacoeconomics. 2007;25(5):365-84 [17488136.001]
  • [Cites] Biometrics. 1989 Sep;45(3):781-95 [2790121.001]
  • [Cites] Ann Intern Med. 1997 Apr 15;126(8):600-7 [9103126.001]
  • [Cites] Bone Marrow Transplant. 1997 Feb;19(3):275-81 [9028558.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):969-73 [7707125.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3302-17 [10986064.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1644-51 [15756658.001]
  • (PMID = 19178124.001).
  • [ISSN] 1170-7690
  • [Journal-full-title] PharmacoEconomics
  • [ISO-abbreviation] Pharmacoeconomics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


60. Pfreundschuh M, Zwick C, Zeynalova S, Dührsen U, Pflüger KH, Vrieling T, Mesters R, Mergenthaler HG, Einsele H, Bentz M, Lengfelder E, Trümper L, Rübe C, Schmitz N, Loeffler M, German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL): Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol; 2008 Mar;19(3):545-52
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
  • BACKGROUND: The addition of etoposide to combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone [etoposide to combination chemotherapy with cyclophosphamide, vincristine and prednisone (CHOEP)] improved outcome of young patients with good-prognosis aggressive lymphoma.
  • PATIENTS AND METHODS: Intention-to-treat analysis of 389 young (18-60 years) patients with good-prognosis (age-adjusted International Prognostic Index = 0, 1) aggressive lymphoma randomized to CHOEP-21 (n = 194) or high CHOEP (n = 195).
  • CONCLUSION: Dose-escalated CHOEP-21 does not provide clinical benefit for young patients with good-prognosis aggressive lymphomas.
  • Since differences between chemotherapy regimens are compressed by the addition of rituximab, the results of this trial have bearing on strategies aiming to improve outcome of good-prognosis aggressive lymphomas in the rituximab era.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18065407.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


61. Broyde A, Boycov O, Strenov Y, Okon E, Shpilberg O, Bairey O: Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma. Am J Hematol; 2009 Jun;84(6):338-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma.
  • The aim of this study was to evaluate the role and prognostic significance of the Ki-67 proliferation index (PI) in non-Hodgkin's lymphoma.
  • Ki-67 was assayed immunohistochemically in tissue samples of 319 patients with newly-diagnosed non-Hodgkin's lymphoma.
  • The mean Ki-67 PI ranged from 26.6% in indolent lymphomas to 97.6% in very aggressive lymphomas (P < 0.001).
  • The index was <45% in 82.8% of indolent lymphomas and >45% in 85% of aggressive lymphomas (AUC = 0.877, P < 0.001).
  • In patients with diffuse large B-cell lymphoma (n = 141), a Ki-67 PI of 70% was found to significantly discriminate patients with good or bad prognosis (AUC = 0.65, P = 0.004).
  • Our results suggest that the mean Ki-67 PI differs by type of lymphoma.
  • A cut-off value of 45% can help differentiate indolent from aggressive disease.
  • In diffuse large B-cell lymphoma, a cut-off value of 70% can distinguish patients with a good and bad prognosis when combined with other prognostic factors of low IPI score and bulky disease.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Ki-67 Antigen / biosynthesis. Lymphoma, Non-Hodgkin / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Survival Rate. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19384938.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


62. Lazar AD, Shpilberg O, Shaklai M, Bairey O: Salvage chemotherapy with dexamethasone, etoposide, ifosfamide and cisplatin (DVIP) for relapsing and refractory non-Hodgkin's lymphoma. Isr Med Assoc J; 2009 Jan;11(1):16-22
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with dexamethasone, etoposide, ifosfamide and cisplatin (DVIP) for relapsing and refractory non-Hodgkin's lymphoma.
  • BACKGROUND: There is currently no standard salvage chemotherapy for the 40-50% of patients with non-Hodgkin's lymphoma who fail first-line treatment.
  • RESULTS: We identified 37 adult patients (mean age 56.3 years): 29 with aggressive lymphoma and 8 with indolent lymphoma.
  • Consolidation with stem cell transplantation was used in 14 patients with aggressive lymphoma and 4 with indolent lymphoma; 14 patients, all with aggressive lymphoma, responded (12 complete, 2 partial).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / therapeutic use. Dexamethasone / therapeutic use. Etoposide / therapeutic use. Female. Humans. Ifosfamide / therapeutic use. Male. Middle Aged. Stem Cell Transplantation. Survival Analysis. Treatment Failure

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19344007.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; DICE protocol
  •  go-up   go-down


63. De Renzo A, Perna F, Persico M, Notaro R, Mainolfi C, de Sio I, Ciancia G, Picardi M, Del Vecchio L, Pane F, Rotoli B: Excellent prognosis and prevalence of HCV infection of primary hepatic and splenic non-Hodgkin's lymphoma. Eur J Haematol; 2008 Jul;81(1):51-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excellent prognosis and prevalence of HCV infection of primary hepatic and splenic non-Hodgkin's lymphoma.
  • BACKGROUND: Primary Hepatic (PHL) and Primary Splenic (PSL) non-Hodgkin's Lymphoma are rare entities.
  • Small series of PHL and PSL have been reported, suggesting a non-fortuitous association with Hepatitis C Virus (HCV) infection.
  • RESULTS: Twenty-five adult patients were identified, six with PHL and 19 with PSL.
  • Twenty-four patients had a B-cell lymphoma, defined as Diffuse Large B-cell lymphoma in 18.
  • Most patients presented with aggressive histological subtypes; 92% were alive at a median follow up of 79 months.
  • [MeSH-major] Hepatitis C / complications. Liver Neoplasms / virology. Lymphoma, Non-Hodgkin / virology. Splenic Neoplasms / virology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Humans. Lymphoma, Large B-Cell, Diffuse. Male. Middle Aged. Prevalence. Prognosis. Recurrence. Remission Induction. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18397390.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


64. Djunic I, Jevtovic DL, Ranin J, Salemovic D, Tomin D, Mihaljevic B: Serbian lymphoma study group (SLG): the prognosis of AIDS-related non-Hodgkin's lymphoma. Biomed Pharmacother; 2008 Jan;62(1):12-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serbian lymphoma study group (SLG): the prognosis of AIDS-related non-Hodgkin's lymphoma.
  • BACKGROUND: The majority of patients with AIDS-related non-Hodgkin's lymphoma (ARL) present with advanced disease, aggressive histological type, B-symptoms, and often with an extranodal localization.
  • Twenty-six patients had an aggressive type of lymphoma while 2 had an indolent type.
  • RESULTS: This study demonstrated that significant factors for OS in patients with ARL were the high International Prognostic Index (P=0.019), previous AIDS event (P=0.04), aggressive histological type of NHL (P=0.007) and extranodal disease (P=0.04).
  • CONCLUSIONS: Our data suggest that aggressive presentation of ARL implicates the need not only for more intensive chemotherapy regimens, but the concomitant usage of HAART, which should result in higher rates of OS in ARL patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Prednisolone / administration & dosage. Prednisone / administration & dosage. Prognosis. Retrospective Studies. Vincristine / administration & dosage. Yugoslavia

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17629445.001).
  • [ISSN] 0753-3322
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol
  •  go-up   go-down


65. Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A: Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Exp Hematol; 2007 Apr;35(4):534-40
Hazardous Substances Data Bank. PODOFILOX .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.
  • OBJECTIVE: To determine the safety and outcome following standard-dose ibritumomab tiuxetan followed by BEAM high-dose chemotherapy and autologous stem cell transplantation (ASCT) in patients with chemo-refractory aggressive non-Hodgkin's lymphoma.
  • PATIENTS AND METHODS: The study included 23 patients, median age 55 years (range, 35-66) with chemo-refractory lymphoma, either primary refractory (n = 11) or in refractory relapse (n = 12).
  • CONCLUSION: Ibritumomab tiuxetan-BEAM and ASCT is relatively safe and may improve outcome in patients with refractory lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Carmustine / administration & dosage. Combined Modality Therapy. Cytarabine / administration & dosage. Disease-Free Survival. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Melphalan / administration & dosage. Middle Aged. Podophyllotoxin / administration & dosage. Salvage Therapy. Transplantation Conditioning. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17379063.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / ibritumomab tiuxetan; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; L36H50F353 / Podophyllotoxin; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM protocol
  •  go-up   go-down


66. Bairey O, Ruchlemer R, Shpilberg O: Non-Hodgkin's lymphomas of the colon. Isr Med Assoc J; 2006 Dec;8(12):832-5
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphomas of the colon.
  • BACKGROUND: Non-Hodgkin's lymphoma of the colon is a rare and consequently poorly studied extranodal lymphoma.
  • Aggressive histology was found in 12 patients: diffuse large B cell lymphoma in 11 and peripheral T cell lymphoma in 1.
  • Three patients had mantle cell lymphoma and two had indolent lymphomas: mucosa-associated lymphoid tissue (n=l) and small lymphocytic (n=l).
  • Disease stage influenced prognosis; six of seven patients with limited-stage DLBCL who received aggressive chemotherapy achieved complete remission and enjoyed prolonged survival, whereas patients with aggressive disseminated disease had resistant disease and poor survival (median 8 months).
  • CONCLUSIONS: Most colonic lymphomas are aggressive B cell lymphomas.
  • Those with limited-stage disease when treated with aggressive chemotherapy may enjoy prolonged survival.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Treatment Outcome
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Prognosis. Registries. Remission Induction. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214096.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


67. Trümper L, Zwick C, Ziepert M, Hohloch K, Schmits R, Mohren M, Liersch R, Bentz M, Graeven U, Wruck U, Hoffmann M, Metzner B, Hasenclever D, Loeffler M, Pfreundschuh M, German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL): Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens. Ann Oncol; 2008 Mar;19(3):538-44
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens.
  • PATIENTS AND METHODS: Randomized phase I/II multicenter four-level (cyclophosphamide: 1000-1200-1400-1600 mg/m2; doxorubicin: 55-60-65-70 mg/m2; etoposide: 375-450-525-600 mg/m2) dose escalation study with CHOEP-14 and CHOEP-21 in young patients (18-60 years) with newly diagnosed aggressive non-Hodgkin's lymphoma.

  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212092.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


68. Bellizzi KM, Miller MF, Arora NK, Rowland JH: Positive and negative life changes experienced by survivors of non-Hodgkin's lymphoma. Ann Behav Med; 2007 Oct;34(2):188-99
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positive and negative life changes experienced by survivors of non-Hodgkin's lymphoma.
  • BACKGROUND: The impact of cancer on adult survivors of aggressive non-Hodgkin's Lymphoma (NHL) is understudied.
  • METHODS: Using the Los Angeles County Cancer Surveillance Program, 744 questionnaires were mailed to adult survivors of NHL: 308 provided complete data for analyses (M age=59.8, SD=14.9).
  • [MeSH-major] Life Change Events. Lymphoma, Non-Hodgkin / psychology. Survivors / psychology
  • [MeSH-minor] Activities of Daily Living / psychology. Adaptation, Psychological. Adult. Aged. Aged, 80 and over. Family Relations. Female. Health Behavior. Humans. Male. Middle Aged. Quality of Life. Sick Role. Socioeconomic Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17927557.001).
  • [ISSN] 0883-6612
  • [Journal-full-title] Annals of behavioral medicine : a publication of the Society of Behavioral Medicine
  • [ISO-abbreviation] Ann Behav Med
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCI NIH HHS / PC / N02-PC-15105; United States / PHS HHS / / U55/CCR 921930-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


69. Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman RR, Niesvizky R, Shore T, Chadburn A, Horne H, Kovacs J, Ding CL, Wegener WA, Horak ID, Goldenberg DM: Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol; 2005 Aug 1;23(22):5044-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
  • PURPOSE: To explore the safety and therapeutic activity of combination anti-B-cell monoclonal antibody therapy in non-Hodgkin's lymphoma (NHL).
  • PATIENTS AND METHODS: Twenty-three patients with recurrent B-cell lymphoma received anti-CD22 epratuzumab 360 mg/m(2) and anti-CD20 rituximab 375 mg/m(2) monoclonal antibodies weekly for four doses each.
  • Sixteen patients had indolent histologies (15 with follicular lymphoma) and seven had aggressive NHL (all diffuse large B-cell lymphoma [DLBCL]).
  • Indolent patients had received a median of one (range, one to six) prior treatment, with 31% refractory to their last therapy and 81% with high-risk Follicular Lymphoma International Prognostic Index scores.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Recurrence. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15955901.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / K23 RR16814
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / epratuzumab; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


70. Huang HQ, Peng YL, Cai QQ, Lin XB, Li YH, Xia ZJ, Lin TY, Sun XF, Zhang L, Xu GC, He YJ, Jiang WQ, Guan ZZ: [Long-term outcomes of 392 non-Hodgkin's lymphoma patients treated with pirarubicin based regimens]. Zhonghua Xue Ye Xue Za Zhi; 2005 Oct;26(10):577-80
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term outcomes of 392 non-Hodgkin's lymphoma patients treated with pirarubicin based regimens].
  • OBJECTIVE: To analyse the effectiveness and toxicity of combined chemotherapy regimen containing pirarubicin (THP) in the treatment of non-Hodgkin's lymphoma (NHL).
  • B-cell and T/NK cell NHL accounted for 68.4% and 23.2% respectively with 56.9% of diffuse large B cell lymphoma and 12.5% of peripheral T cell lymphoma.
  • CONCLUSION: The efficacy of THP based regimen CTOP for the treatment of aggressive NHL is promising.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / analogs & derivatives. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16532963.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 80168379AG / Doxorubicin; D58G680W0G / pirarubicin
  •  go-up   go-down


71. Pro B, Fayad L, McLaughlin P, Romaguera J, Hagemeister FB, Rodriguez MA, Goy A, Loyer E, Younes A: Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma; 2006 Mar;47(3):481-5
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma.
  • Patients included in the present study had recurrent or refractory aggressive non-Hodgkin's lymphoma (NHL), had received two to three prior treatment regimens, and had good performance status and marrow reserve.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Neutrophils / drug effects. Paclitaxel / administration & dosage. Topotecan / administration & dosage
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Filgrastim. Humans. Injections, Intravenous. Injections, Subcutaneous. Leukocyte Count. Male. Middle Aged. Recombinant Proteins. Recurrence. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16396772.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A58010674 / pegfilgrastim; 7M7YKX2N15 / Topotecan; P88XT4IS4D / Paclitaxel; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


72. Corazzelli G, Russo F, Capobianco G, Marcacci G, Della Cioppa P, Pinto A: Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study. Ann Oncol; 2006 May;17 Suppl 4:iv18-24
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
  • BACKGROUND: The prognosis of patients with aggressive non-Hodgkin's lymphoma (NHL) relapsing or progressing after front-line therapy remains poor.
  • RESULTS: Fourteen patients (median age 63 years, range 37-78 years) with relapsed (n = 9) or primary progressive (n = 5) aggressive (diffuse large cell, mantle cell, follicular G3), advanced (stage IV 71%), poor risk (IPI 3-5 50%) NHL were accrued in this pilot study.
  • CONCLUSIONS: Based on the results of this pilot study, we conclude that the R-GIFOX regimen is feasible, tolerable, effective and able to mobilize peripheral stem cells in patients with relapsed and refractory aggressive NHL.

  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702180.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 4F4X42SYQ6 / Rituximab; B76N6SBZ8R / gemcitabine; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


73. Iagaru A, Gambhir SS, Goris ML: 90Y-ibritumomab therapy in refractory non-Hodgkin's lymphoma: observations from 111In-ibritumomab pretreatment imaging. J Nucl Med; 2008 Nov;49(11):1809-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 90Y-ibritumomab therapy in refractory non-Hodgkin's lymphoma: observations from 111In-ibritumomab pretreatment imaging.
  • Radioimmunotherapy is an effective treatment for non-Hodgkin's lymphoma (NHL).
  • This observation suggests that patients with bulky disease may require more aggressive management.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Indium Radioisotopes. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Radioimmunotherapy. Recurrence. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Nucl Med. 2009 Jun;50(6):1010-1; author reply 1011-12 [19443584.001]
  • (PMID = 18927323.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Indium Radioisotopes; 0 / ibritumomab tiuxetan
  •  go-up   go-down


74. Yang DH, Min JJ, Jeong YY, Ahn JS, Kim YK, Cho SH, Chung IJ, Bom HS, Kim HJ, Lee JJ: The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma. Ann Hematol; 2009 May;88(5):425-32
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma.
  • We investigated the concomitant interim response of patients with aggressive non-Hodgkin's lymphoma (NHL) using multi-detector row computerized tomography (CT) and (18)F-fluoro-2-deoxy-D: -glucose-positron emission tomography (PET)/CT for prediction of clinical outcomes.
  • One hundred six newly diagnosed patients with aggressive NHL were enrolled.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Neoplasm, Residual / diagnosis. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Fluorodeoxyglucose F18. Humans. Male. Metabolism. Middle Aged. Prognosis. Remission Induction. Survival Analysis. T-Lymphocytes. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19002686.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


75. Kahn ST, Flowers C, Lechowicz MJ, Hollenbach K, Johnstone PA: Value of PET restaging after chemotherapy for non-Hodgkin's lymphoma: implications for consolidation radiotherapy. Int J Radiat Oncol Biol Phys; 2006 Nov 15;66(4):961-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of PET restaging after chemotherapy for non-Hodgkin's lymphoma: implications for consolidation radiotherapy.
  • PURPOSE/OBJECTIVE: Patients treated for non-Hodgkin's Lymphoma (NHL) frequently are restaged for response using positron emission tomography (PET) scanning.
  • Multivariate analysis adjusted for age, indolent vs. aggressive histology, and time from chemotherapy to PET revealed PET positive scans (RR = 30.5; 95%CI = 5.9, 156.4), lack of RT (RR = 5.25; 95%CI = 1.26, 21.79), and Stage III/IV presentation (RR = 4.35; 95%CI = 1.03, 20) predicted increased likelihood of recurrence.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / radionuclide imaging. Lymphoma, Non-Hodgkin / therapy. Neoplasm Recurrence, Local / radiotherapy. Positron-Emission Tomography / methods. Radiotherapy, Adjuvant / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Reproducibility of Results. Retrospective Studies. Sensitivity and Specificity. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1278; author reply 1278 [17336228.001]
  • (PMID = 17145526.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


76. Paydas S, Ergin M, Erdogan S, Seydaoglu G: Cyclooxygenase-2 expression in non-Hodgkin's lymphomas. Leuk Lymphoma; 2007 Feb;48(2):389-95

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 expression in non-Hodgkin's lymphomas.
  • Cox-2 has been studied in solid tumors; however, studies about the role of Cox-2 in non-Hodgkin's lymphomas (NHL) are limited.
  • In histological terms, 60 cases (33%) had low grade and 117 (67%) had aggressive lymphoma.
  • There was an important association between aggressive histology and Cox-2 expression: Cox-2 was negative in about half of the cases with indolent morphology, while two thirds of the Cox-2 positive cases had aggressive histology (p = 0.036).
  • In conclusion Cox-2 expression is seen about 60% of the cases with NHL and is associated with aggressive morphology.
  • [MeSH-major] Cyclooxygenase 2 / metabolism. Lymphoma, Large B-Cell, Diffuse / enzymology. Lymphoma, Mantle-Cell / enzymology. Lymphoma, Non-Hodgkin / enzymology. Lymphoma, T-Cell, Peripheral / enzymology. Membrane Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325901.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


77. García JF, Mollejo M, Fraga M, Forteza J, Muniesa JA, Pérez-Guillermo M, Pérez-Seoane C, Rivera T, Ortega P, Piris MA: Large B-cell lymphoma with Hodgkin's features. Histopathology; 2005 Jul;47(1):101-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large B-cell lymphoma with Hodgkin's features.
  • AIMS: To describe the features of a series of nine cases of diffuse large B-cell lymphoma (DLBCL) showing morphological and immunophenotypic features that are intermediate with Hodgkin's lymphoma (HL).
  • Histopathologically, tumours showed diffuse large cell areas in a polymorphous background, with pleomorphic cytology and the common presence of Hodgkin's and Reed-Sternberg cells.
  • CONCLUSIONS: These findings suggest that DLBCLs with HL features constitute a distinctive subgroup of aggressive lymphomas whose neoplastic growth and peculiar characteristics could be facilitated by a particular microenvironment found in the mediastinum.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / analysis. DNA-Binding Proteins / analysis. DNA-Binding Proteins / genetics. Diagnosis, Differential. Female. Gene Rearrangement. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Ki-67 Antigen / analysis. Male. Middle Aged. Mutation. Neoplasm Staging. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-bcl-2 / analysis. Proto-Oncogene Proteins c-bcl-6. Transcription Factors / analysis. Transcription Factors / genetics. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982329.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


78. Bociek RG: Adult Burkitt's lymphoma. Clin Lymphoma; 2005 Jun;6(1):11-20
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult Burkitt's lymphoma.
  • Burkitt's lymphoma is a mature B-cell lymphoma that is characterized by a rapid proliferative rate and propensity for extranodal sites of involvement such as the gastrointestinal tract and central nervous system.
  • This subtype of non-Hodgkin's lymphoma is associated with unique cytogenetic translocations involving the c-MYC oncogene on chromosome 8, which appears to be involved in the pathogenesis of this disease.
  • Although current literature is limited by a lack of randomized trials, Burkitt's lymphoma appears to be curable in a high proportion of cases if treated with aggressive multiagent chemotherapy regimens.
  • Patients with HIV-associated Burkitt's lymphoma appear to have a better prognosis today, which is likely a result of more effective antiretroviral therapy and the ability to treat selected patients with more aggressive chemotherapeutic regimens than before.
  • This article will review the epidemiologic, biologic, diagnostic, and therapeutic aspects of Burkitt's lymphoma in adults.
  • [MeSH-major] Burkitt Lymphoma
  • [MeSH-minor] Adult. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15989701.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


79. Darom A, Gomatos IP, Leandros E, Chatzigianni E, Panousopoulos D, Konstadoulakis MM, Androulakis G: Molecular markers (PECAM-1, ICAM-3, HLA-DR) determine prognosis in primary non-Hodgkin's gastric lymphoma patients. World J Gastroenterol; 2006 Mar 28;12(12):1924-32
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular markers (PECAM-1, ICAM-3, HLA-DR) determine prognosis in primary non-Hodgkin's gastric lymphoma patients.
  • AIM: To investigate the prognostic significance of PECAM-1, ICAM-3 and HLA-DR antigens in patients with primary non-Hodgkin's gastric lymphoma.
  • METHODS: We immunohistochemically studied PECAM-1, ICAM-3 and HLA-DR antigen expression in 36 B-cell MALT-type primary gastric lymphoma patients.
  • Ten non-malignant and ten healthy gastric tissue specimens were used as controls.
  • RESULTS: HLA-DR antigen expression was detected in 33 gastric lymphoma patients (91.7%) and 6 non-malignant patients (54.5%).
  • ICAM-3 expression was observed on the tumor cells of 17 patients (47.2%), while 5 non-malignant patients (50%) were stained positive as well.
  • Their combined use may help us to identify high-risk patients who could benefit from more aggressive therapeutic protocols.
  • [MeSH-major] Antigens, CD / analysis. Antigens, CD31 / analysis. Cell Adhesion Molecules / analysis. HLA-DR Antigens / analysis. Lymphoma, Non-Hodgkin / chemistry. Stomach Neoplasms / chemistry
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Cancer Biol. 1991 Feb;2(1):47-54 [1912518.001]
  • [Cites] Eur J Clin Invest. 1990 Oct;20(5):481-6 [2124977.001]
  • [Cites] Lancet. 1992 Nov 7;340(8828):1120-4 [1279332.001]
  • [Cites] Nature. 1992 Dec 3;360(6403):481-4 [1448173.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87 [1281237.001]
  • [Cites] J Exp Med. 1993 Aug 1;178(2):449-60 [8340753.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):401-9 [7688183.001]
  • [Cites] Int J Cancer. 1993 Sep 30;55(3):371-4 [7690738.001]
  • [Cites] Eur J Immunol. 1993 Nov;23(11):2799-806 [8223855.001]
  • [Cites] J Biol Chem. 1995 Jan 13;270(2):877-84 [7822326.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):706-18; discussion 718-20 [7794075.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1196-200 [7590692.001]
  • [Cites] Oncology. 1996 Mar-Apr;53(2):127-32 [8604238.001]
  • [Cites] Leukemia. 1996 May;10(5):907-8 [8656688.001]
  • [Cites] Br J Oral Maxillofac Surg. 1996 Feb;34(1):37-41 [8645680.001]
  • [Cites] J Mol Med (Berl). 1996 Jul;74(7):353-63 [8841948.001]
  • [Cites] Tissue Antigens. 1996 Oct;48(4 Pt 1):271-7 [8946680.001]
  • [Cites] Virchows Arch. 1996 Dec;429(6):377-82 [8982383.001]
  • [Cites] Am J Clin Pathol. 1997 May;107(5):534-41 [9128265.001]
  • [Cites] Vet Pathol. 1997 Jan;34(1):61-73 [9150551.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):326-9 [9221813.001]
  • [Cites] Int J Cancer. 1997 Dec 19;74(6):582-7 [9421352.001]
  • [Cites] Clin Cancer Res. 1998 Jan;4(1):31-6 [9516949.001]
  • [Cites] Tissue Cell. 1998 Jun;30(3):377-82 [10091339.001]
  • [Cites] APMIS. 1999 Apr;107(4):383-8 [10230691.001]
  • [Cites] Microvasc Res. 1999 May;57(3):292-7 [10329255.001]
  • [Cites] Oncology. 1985;42(2):97-103 [3887261.001]
  • [Cites] Immunobiology. 1985 Apr;169(3):228-49 [3873401.001]
  • [Cites] Eur J Immunol. 1986 Feb;16(2):172-81 [2420606.001]
  • [Cites] Int J Cancer. 1986 Oct 15;38(4):459-64 [2428757.001]
  • [Cites] Ann Surg. 1987 Jun;205(6):634-40 [3592805.001]
  • [Cites] J Clin Pathol. 1987 Jul;40(7):760-5 [3305585.001]
  • [Cites] J Clin Pathol. 1987 Sep;40(9):948-58 [3312304.001]
  • [Cites] Blood. 2000 Mar 15;95(6):1900-10 [10706853.001]
  • [Cites] Cancer Metastasis Rev. 1999;18(3):345-57 [10721489.001]
  • [Cites] In Vivo. 2000 Jan-Feb;14(1):199-208 [10757078.001]
  • [Cites] World J Surg. 2000 May;24(5):608-14 [10787085.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 2000;48(3):201-4 [10912626.001]
  • [Cites] Lung Cancer. 2000 Sep;29(3):169-77 [10996419.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12):1641-9 [11117785.001]
  • [Cites] Pathologica. 2000 Dec;92(6):503-15 [11234301.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1258-64 [11483337.001]
  • [Cites] Hepatogastroenterology. 2001 Jul-Aug;48(40):1202-5 [11490834.001]
  • [Cites] Int J Cancer. 2001 Nov15;94(4):599-604 [11745451.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1185-91 [12006536.001]
  • [Cites] Surgery. 2002 Jul;132(1):20-6 [12110791.001]
  • [Cites] Br J Surg. 1970 Dec;57(12):877-83 [5487028.001]
  • [Cites] Science. 1981 Jun 12;212(4500):1229-38 [6165083.001]
  • [Cites] J Cell Biol. 1982 Dec;95(3):974-81 [6185506.001]
  • [Cites] Cell. 1984 Jan;36(1):1-13 [6198089.001]
  • [Cites] Br Med Bull. 1987 Jan;43(1):217-27 [3315098.001]
  • [Cites] Biochim Biophys Acta. 1989 Feb;948(3):305-26 [2465781.001]
  • [Cites] Scand J Immunol. 1989 Aug;30(2):129-64 [2474849.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1208-17 [2670184.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1154-7 [2400966.001]
  • [Cites] Surg Clin North Am. 1992 Apr;72(2):423-31 [1549801.001]
  • (PMID = 16610000.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD31; 0 / Cell Adhesion Molecules; 0 / HLA-DR Antigens; 0 / ICAM3 protein, human
  • [Other-IDs] NLM/ PMC4087519
  •  go-up   go-down


80. Thomson KJ, Morris EC, Bloor A, Cook G, Milligan D, Parker A, Clark F, Yung L, Linch DC, Chakraverty R, Peggs KS, Mackinnon S: Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol; 2009 Jan 20;27(3):426-32
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma.
  • PURPOSE: The role of allogeneic transplantation with reduced-intensity conditioning in diffuse large B-cell lymphoma (DLBCL) is currently unclear, with relatively little published data.
  • We report the outcome of reduced-intensity transplantation (RIT) in a cohort of 48 consecutive patients with relapsed/refractory DLBCL (30 patients with de novo disease and 18 patients with transformed follicular lymphoma) who underwent transplantation with an alemtuzumab-containing regimen, with a median follow-up of 52 months.
  • [MeSH-major] Bone Marrow Transplantation / methods. Lymphoma, Large B-Cell, Diffuse / therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / administration & dosage. Antineoplastic Agents / administration & dosage. Graft vs Host Disease / etiology. Humans. Melphalan / administration & dosage. Middle Aged. Transplantation Conditioning / methods. Transplantation, Homologous. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19064981.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan
  •  go-up   go-down


81. Hess G, Flohr T, Kolbe K, Bonn S, Schuler M, Derigs HG, Huber C: Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin's lymphoma. Ann Hematol; 2006 Nov;85(11):769-79
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin's lymphoma.
  • To better define the role of rituximab in salvage and high-dose therapy (HDT) for relapsed or refractory non-Hodgkin's lymphoma (NHL), patients treated before the implementation of rituximab in salvage and HDT (n = 57, control group) were compared with patients with rituximab included in this procedure (n = 36, study group).
  • All patients had been antibody-naive at this point, and analyses were performed separately for 22 and 31 patients with aggressive, and 14 and 26 patients with indolent NHL, respectively.
  • Despite the absence of differences in stem cell collection, haematopoietic recovery was delayed in patients with aggressive NHL treated in the study group: median days to absolute neutrophil count more than 0.5 x 10(9)/l, 11 vs 10 (p = 0.01), and platelets more than 20 x 10(9)/l, 14 vs 11 (p = 0.0005), with an increased requirement for platelet transfusions.
  • No similar observations were made in indolent lymphoma patients.
  • Remission rates were superior for patients with aggressive NHL in the study group.
  • For patients with indolent lymphoma, no comparable benefit was detectable.
  • Our data support the use of rituximab in HDT for patients with aggressive NHL.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Lymphoma, B-Cell / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Hematopoiesis. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Neoplasm Staging. Recurrence. Remission Induction. Rituximab. Survival Analysis. Transplantation Conditioning / methods. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16896912.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


82. Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, Schmitz N, German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL): Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol; 2007 Jan;18(1):149-57
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
  • BACKGROUND: Central nervous system (CNS) relapse is a devastating and usually fatal complication of aggressive lymphoma.
  • We analyzed the patients treated on protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) between 1990 and 2000, evaluated the rate and prognostic factors for CNS recurrence and developed a risk model trying to identify subsets of patients suitable for future prophylactic strategies.
  • The protocol asked for an intrathecal (i.th.) prophylaxis in patients with lymphoblastic lymphoma only (n=17), but overall 71 patients (71 of 1693=4.2%) received prophylaxis by decision of the treating physicians.
  • Elderly patients presenting with both an elevated LDH and lymphoma involvement in liver, bladder or adrenals had an up to 15-fold risk of spread of the disease to the CNS.
  • CONCLUSION: The incidence of CNS relapse in 1693 patients treated for aggressive lymphomas on DSHNHL protocols from 1990 to 2000 was low (2.2%), although CNS prophylaxis was administered to <5% of patients.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17018708.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone
  •  go-up   go-down


83. Pereira J, Bellesso M, Pracchia LF, Neto AE, Beitler B, de Almeida Macedo MC, Dias LC, Dorlhiac-Llacer PE, Dulley FL, Chamone D: Modified Magrath IVAC regimen as second-line therapy for relapsed or refractory aggressive non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil. Leuk Res; 2006 Jun;30(6):681-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modified Magrath IVAC regimen as second-line therapy for relapsed or refractory aggressive non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil.
  • BACKGROUND: The purpose of this retrospective study was to investigate the efficacy, toxicity and mobilization rate after modified Magrath IVAC (mIVAC) chemotherapy regimen prescribed in relapsed disease (RD) or primary refractory disease (PRD) in aggressive non-Hodgkin lymphoma (NHL).
  • The most frequent histopathological subgroup was diffuse large B-cell lymphoma (DLCL-B) (n=21/24), 13 (54%) were considered RD and 11 (46%) PRD.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell / prevention & control. Lymphoma, Non-Hodgkin / prevention & control. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Brazil. Cytarabine / administration & dosage. Developing Countries. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Recurrence. Transplantation, Autologous

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16288806.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; UM20QQM95Y / Ifosfamide; IVAC protocol
  •  go-up   go-down


84. Leonard JP, Link BK, Emmanouilides C, Gregory SA, Weisdorf D, Andrey J, Hainsworth J, Sparano JA, Tsai DE, Horning S, Krieg AM, Weiner GJ: Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res; 2007 Oct 15;13(20):6168-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma.
  • EXPERIMENTAL DESIGN: Patients with relapsed/refractory CD20+ B cell non-Hodgkin's lymphoma received i.v. rituximab (375 mg/m2/week for 4 weeks) and PF-3512676 weekly for 4 weeks either i.v. (0.04, 0.16, 0.32, or 0.48 mg/kg) or s.c. (0.01, 0.04, 0.08, or 0.16 mg/kg).
  • CONCLUSION: Brief or extended-duration PF-3512676 can be safely administered in combination with rituximab in patients with relapsed/refractory non-Hodgkin's lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Lymphoma, Non-Hodgkin / drug therapy. Oligodeoxyribonucleotides / administration & dosage. Toll-Like Receptors / agonists
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / biosynthesis. Cohort Studies. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Recurrence. Rituximab. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17947483.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Oligodeoxyribonucleotides; 0 / ProMune; 0 / Toll-Like Receptors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


85. Scheinpflug K, Schalk E, Mohren M: Staphylococcal scalded skin syndrome in an adult patient with T-lymphoblastic non-Hodgkin's lymphoma. Onkologie; 2008 Nov;31(11):616-9
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staphylococcal scalded skin syndrome in an adult patient with T-lymphoblastic non-Hodgkin's lymphoma.
  • PATIENT AND METHODS: We report a case of SSSS in a young female patient with T-lymphoblastic lymphoma, who survived this potentially lethal complication.
  • CONCLUSIONS: To the best of our knowledge, this is the first case of SSSS in an adult patient with T-lymphoblastic non-Hodgkin's lymphoma.
  • Clinicians should be aware of SSSS as a rare but potentially fatal disorder, particularly in adult patients with malignancies undergoing aggressive chemotherapy.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / complications. Lymphoma, T-Cell, Cutaneous / diagnosis. Staphylococcal Scalded Skin Syndrome / diagnosis. Staphylococcal Scalded Skin Syndrome / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19145095.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 43B2M34G2V / Floxacillin
  •  go-up   go-down


86. Mey UJ, Orlopp KS, Flieger D, Strehl JW, Ho AD, Hensel M, Bopp C, Gorschlüter M, Wilhelm M, Birkmann J, Kaiser U, Neubauer A, Florschütz A, Rabe C, Hahn C, Glasmacher AG, Schmidt-Wolf IG: Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer Invest; 2006 Oct;24(6):593-600
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
  • A total of 53 patients with relapsed or resistant aggressive B-cell NHL were analyzed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Female. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Prospective Studies. Rituximab. Survival Rate. Treatment Outcome

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16982464.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin; DHAP protocol
  •  go-up   go-down


87. Salem AK: Prevalence of HCV among Yemeni patients with non-Hodgkin's lymphoma at AI-Thawra teaching hospital. Gulf J Oncolog; 2009 Jan;(5):22-9
MedlinePlus Health Information. consumer health - Hepatitis C.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of HCV among Yemeni patients with non-Hodgkin's lymphoma at AI-Thawra teaching hospital.
  • BACKGROUND: Epidemiological studies in different parts of the world have revealed controversial results on the association between HCV infection and Non-Hodgkin's lymphomas.
  • The prevalence of HCV infection in patients with NHLs was compared to that in a non-lymphomatous control group consisted of all patients checked for HCV infection with several acute medical conditions in the same hospital who were coming from different parts of the country.
  • Nonetheless, positive associations were noted for indolent type [OR=4.49, 95% CI 1.87-10.78] and for aggressive type as well [OR=4.2195% CI 2.69-6.59].
  • [MeSH-major] Hepatitis C / epidemiology. Lymphoma, Non-Hodgkin / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Viral / blood. Child. Child, Preschool. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Prevalence. Yemen. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20084782.001).
  • [ISSN] 2078-2101
  • [Journal-full-title] The Gulf journal of oncology
  • [ISO-abbreviation] Gulf J Oncolog
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Kuwait
  • [Chemical-registry-number] 0 / Antibodies, Viral
  •  go-up   go-down


88. Welt A, Schütt P, Derks C, Ebeling P, Müller S, Metz K, Anhuf J, Moritz T, Seeber S, Nowrousian MR: Long-term results of a phase-I/II study of sequential high-dose chemotherapy with autologous stem cell transplantation in the initial treatment of aggressive non-Hodgkin's lymphoma. Tumori; 2007 Sep-Oct;93(5):409-16
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of a phase-I/II study of sequential high-dose chemotherapy with autologous stem cell transplantation in the initial treatment of aggressive non-Hodgkin's lymphoma.
  • AIMS AND BACKGROUND: To improve the survival of patients with aggressive non-Hodgkin's lymphoma, we evaluated a risk-adapted therapeutic approach using high-dose (HD) or conventional-dose (CD) chemotherapy (CT) for poor-risk and good-risk patients, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / therapy. Neoplasm Recurrence, Local / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Carboplatin / administration & dosage. Combined Modality Therapy. Dexamethasone / administration & dosage. Etoposide / administration & dosage. Feasibility Studies. Female. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Remission Induction. Survival Rate. Transplantation, Autologous. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18038870.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


89. Usui N, Yano S, Asai O, Dobashi N, Osawa H, Takei Y, Sugiyama K, Takahara S, Otubo H, Saito T, Okawa Y, Hagino T, Kaito K, Kobayashi M: Long-term follow-up high-dose chemotherapy (drug-only program) followed by autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas. Clin Lymphoma; 2005 Jun;6(1):31-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up high-dose chemotherapy (drug-only program) followed by autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas.
  • PURPOSE: To investigate the feasibility of high-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) for aggressive non-Hodgkin's lymphoma (NHL), we conducted HDCT with ASCT using a drug-only protocol without total body irradiation.
  • Previously untreated and treated adult patients with aggressive lymphoma were enrolled onto this study.
  • Retrospective immunophenotypic examination indicated that the majority of the patients were diagnosed with B-cell lymphoma.
  • CONCLUSIONS: High-dose chemotherapy followed by ASCT is one of the available consolidation therapies for aggressive NHL, and additional involved-field irradiation could play a role in the management of patients with NHL who do not exhibit a CR after treatment with HDCT containing a drug-only program.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Lymphoma, Non-Hodgkin / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Humans. Male. Middle Aged. Prednisone / therapeutic use. Survival Analysis. Transplantation, Autologous. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15989704.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


90. van Imhoff GW, van der Holt B, Mackenzie MA, Van't Veer MB, Wijermans PW, Ossenkoppele GJ, Schouten HC, Sonneveld P, Steijaert MM, Kluin PM, Kluin-Nelemans HC, Verdonck LF, Dutch-Belgian Hemato-Oncology Cooperative Group: Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. J Clin Oncol; 2005 Jun 1;23(16):3793-801
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
  • PURPOSE: Timing, appropriate amount, and composition of treatment before high-dose therapy and autologous stem-cell transplantation (ASCT) in patients with poor-risk, aggressive non-Hodgkin's lymphoma (NHL) are still unknown.
  • We conducted two consecutive multicenter phase II trials with up-front, high-dose, sequential chemotherapy and ASCT in poor-risk, aggressive NHL.
  • PATIENTS AND METHODS: Between 1994 and 2001, 147 newly diagnosed, poor-risk, aggressive NHL patients, age < or = 65 years with stage III to IV and lactate dehydrogenase (LDH) more than 1.5x upper limit of normal (ULN), entered the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) -27 and HOVON-40 trials.
  • RESULTS: Patient characteristics in both trials were comparable: 80% had diffuse large B-cell lymphoma, 77% had stage IV disease, and median LDH levels were 3.1x ULN.
  • CONCLUSION: In patients with poor-risk, aggressive NHL, addition of intensified CHOP before up-front, high-dose, sequential therapy and ASCT significantly improved the duration of response and survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Prednisone / administration & dosage. Prognosis. Remission Induction. Risk Factors. Stem Cell Transplantation. Survival Rate. Transplantation, Autologous. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15809447.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


91. Aurer I, Mitrović Z, Nemet D, Radman I, Sertić D, Serventi-Seiwerth R, Stern-Padovan R, Santek F, Nola M, Mrsić M, Labar B: Treatment of relapsed or refractory aggressive non-hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICE. J Chemother; 2008 Oct;20(5):640-4
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of relapsed or refractory aggressive non-hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICE.
  • We report the outcomes of 45 patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) treated with a combination of ifosfamide, carboplatinum and etoposide (ICE) and 28 patients treated with a combination of ifosfamide, methotrexate and etoposide (IMVP) during two 5-year periods.
  • Changing from IMVP to ICE does not substantially improve the outcome of patients with relapsed or refractory aggressive NHL.
  • Patients with relapsed/refractory aggressive B-NHL do not have a superior outcome in comparison to those with T-NHL if treated with chemotherapy alone.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Disease-Free Survival. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Kaplan-Meier Estimate. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Salvage Therapy / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19048695.001).
  • [ISSN] 1973-9478
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


92. Zhu J, Wang WY, Jiang M, Yang Y, Hou M: [Correlation between VEGF expression and clinical characteristic of patient with non-Hodgkin's lymphoma: an initial study]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 May;39(3):418-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation between VEGF expression and clinical characteristic of patient with non-Hodgkin's lymphoma: an initial study].
  • OBJECTIVE: To study whether VEGF expression is associated with clinical characteristics such as gender, age, aggressive, stage, B-symptoms and complete remission (CR) rate of patients with non-Hodgkin's lymphoma.
  • RESULTS: Comparing VEGF positive rates grouped by sexuality, age, aggressive grade or stage, the results suggested no significant correlation between them.
  • CONCLUSIONS: Expression of VEGF is associated with B-symptoms and poor response to chemotherapy in patients with non-Hodgkin's lymphoma, there was not any relationship to have been found between VEGF expression and sexuality, age, aggressive grade, stage.
  • [MeSH-major] Lymphoma, Non-Hodgkin / metabolism. Lymphoma, Non-Hodgkin / pathology. Vascular Endothelial Growth Factor A / biosynthesis
  • [MeSH-minor] Adult. Chi-Square Distribution. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18575329.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


93. Utkan G, Tek I, Kocer M, Muallaoglu S, Durnal AG, Arslan UY, Celenkoglu G, Tokluoglu S, Alkis N: Blood viscosity in patients with diffuse large B cell non-Hodgkin's lymphoma. Exp Oncol; 2006 Dec;28(4):326-7
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blood viscosity in patients with diffuse large B cell non-Hodgkin's lymphoma.
  • The aim of the study was to evaluate blood viscosity as possible marker of disease progression in patients with newly diagnosed non-Hodgkin's lymphoma (NHL).
  • METHODS: The viscosity of blood samples from 20 patients with newly diagnosed aggressive NHL (stage I, n=7; stage II, n=4; stage III, n=7; stage IV, n=2) was analyzed using Brookfield DV-II + (USA) machine.
  • [MeSH-major] Blood Viscosity. Lymphoma, B-Cell / blood. Lymphoma, Large B-Cell, Diffuse / blood
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17285120.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  •  go-up   go-down


94. Josting A, Sieniawski M, Glossmann JP, Staak O, Nogova L, Peters N, Mapara M, Dörken B, Ko Y, Metzner B, Kisro J, Diehl V, Engert A: High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann Oncol; 2005 Aug;16(8):1359-65
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.
  • BACKGROUND: Combination chemotherapy can cure patients with non-Hodgkin's lymphoma (NHL), but those who suffer treatment failure or relapse still have a poor prognosis.
  • PATIENTS AND METHODS: Inclusion criteria were age 18-65 years, histologically proven primary progressive or relapsed aggressive NHL and eligibility for HDCT.
  • This program is currently being modified by addition of rituximab for patients with relapsed aggressive NHL.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15939712.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine
  •  go-up   go-down


95. Sawka CA, Shepherd FA, Franssen E, Brandwein J, Dotten DA, Routy JP, Walker IR, St-Louis J, Taylor M, Arts K, Crump M, Foote M: A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma. Biotechnol Annu Rev; 2005;11:381-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
  • Non-Hodgkin's lymphoma (NHL) remains an important complication of associated HIV infection despite advances in antiretroviral therapy (ART), and the optimum chemotherapy regimen for this disease remains to be defined.
  • Patients with aggressive histology HIV-related NHL who were previously untreated with chemotherapy, and who had no active opportunistic infection were eligible for the study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Bleomycin / adverse effects. Bleomycin / therapeutic use. CD4 Lymphocyte Count. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Etoposide / administration & dosage. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Filgrastim. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Injections, Intravenous. Injections, Subcutaneous. Male. Middle Aged. Prednisone / adverse effects. Prednisone / therapeutic use. Prospective Studies. Recombinant Proteins. Survival Analysis. Treatment Outcome. Vincristine / adverse effects. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16216784.001).
  • [ISSN] 1387-2656
  • [Journal-full-title] Biotechnology annual review
  • [ISO-abbreviation] Biotechnol Annu Rev
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Recombinant Proteins; 11056-06-7 / Bleomycin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; PVI5M0M1GW / Filgrastim; VB0R961HZT / Prednisone; VACOP-B protocol
  •  go-up   go-down


96. Vignot S, Ledoussal V, Nodiot P, Bourguignat A, Janvier M, Mounier N, Chérel P, Floiras JL, Turpin F: Non-Hodgkin's lymphoma of the breast: a report of 19 cases and a review of the literature. Clin Lymphoma; 2005 Jun;6(1):37-42
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma of the breast: a report of 19 cases and a review of the literature.
  • PURPOSE: Non-Hodgkin's lymphoma of the breast represents 0.04%-0.50% of malignant lesions of the mammary gland.
  • MATERIALS AND METHODS: Between 1982 and 1997, 19 patients with breast lymphoma were diagnosed, treated, and followed at this institution.
  • All but one were cases of aggressive B-cell lymphoma.
  • [MeSH-major] Breast Neoplasms / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms, Male / mortality. Breast Neoplasms, Male / therapy. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15989705.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


97. Baldissera RC, Nucci M, Vigorito AC, Maiolino A, Simões BP, Lorand-Metze I, Aranha FJ, Miranda EC, Pagnano KB, Ruiz MA, Moraes AA, De Souza CA: Frontline therapy with early intensification and autologous stem cell transplantation versus conventional chemotherapy in unselected high-risk, aggressive non-Hodgkin's lymphoma patients: a prospective randomized GEMOH report. Acta Haematol; 2006;115(1-2):15-21
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frontline therapy with early intensification and autologous stem cell transplantation versus conventional chemotherapy in unselected high-risk, aggressive non-Hodgkin's lymphoma patients: a prospective randomized GEMOH report.
  • This prospective multicenter randomized trial compares conventional with early intensification with high-dose sequential chemotherapy (HDS) and autologous stem cell transplantation (ASCT) as frontline therapy in high-risk non-Hodgkin lymphomas (NHL).
  • Newly diagnosed patients with aggressive high-risk [intermediate-high (HI) and high-risk (HR)] NHL according to the international prognosis index (IPI) were randomized to receive 12-week VACOP-B (arm A, 27 patients) or 6-week VACOP-B followed by HDS and ASCT (arm B, 29 patients).
  • Abbreviated chemotherapy followed by intensification with HDS-ASCT does not seem to be superior to conventional chemotherapy in HI/HR aggressive NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Prognosis. Remission Induction. Risk Factors. Transplantation, Autologous. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16424644.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; VACOP-B protocol
  •  go-up   go-down


98. Kemp S, Gallagher G, Kabani S, Noonan V, O'Hara C: Oral non-Hodgkin's lymphoma: review of the literature and World Health Organization classification with reference to 40 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Feb;105(2):194-201
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral non-Hodgkin's lymphoma: review of the literature and World Health Organization classification with reference to 40 cases.
  • Forty cases of oral cavity non-Hodgkin's lymphoma (NHL) were evaluated for sex, age, location, clinical presentation, and World Health Organization (WHO) histological subtype.
  • Most of the lymphomas were of B cell lineage (98%), and the majority of these B cell lymphomas (58%) were histologically subtyped as diffuse large B cell lymphoma, which is considered to have an aggressive clinical course.
  • [MeSH-major] International Classification of Diseases. Jaw Neoplasms / classification. Lymphoma, Non-Hodgkin / classification. Mouth Neoplasms / classification
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gene Rearrangement. Humans. Immunophenotyping. Lymphoma, B-Cell / classification. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Oral Health.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17604660.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 62
  •  go-up   go-down


99. Peral-Cagigal B, Galdeano-Arenas M, Crespo-Pinilla JI, García-Cantera JM, Sánchez-Cuéllar LA, Verrier-Hernández A: Centrofacial angiocentric lymphoma. Med Oral Patol Oral Cir Bucal; 2005 Jan-Feb;10(1):92-4; 90-2
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Centrofacial angiocentric lymphoma.
  • The centrofacial angiocentric lymphoma is a rare lymphoid neoplasm, with an often-difficult diagnosis due to the non-specific clinical picture.
  • This lymphoma is an aggressive Non-Hodgkin's (NHL) type, which is normally found in the upper respiratory tract (predominantly in the nasal cavity), and has an ominous prognosis, as the average survival rate is between 12 and 18 months (1).
  • After performing a number of diagnostic tests, it was found histologically that the patient had an extranodal T-cell lymphoma of the nasal type (also known as T-cell angiocentric lymphoma).
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Lymphoma, T-Cell / diagnosis
  • [MeSH-minor] Adult. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15627913.001).
  • [ISSN] 1698-4447
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


100. Tsartsidze E, Betaneli M, Sharikadze N, Shavidze N, Seskuria N: Treatment of aggressive non-Hodgkin's lymphomas. Georgian Med News; 2007 Apr;(145):30-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of aggressive non-Hodgkin's lymphomas.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease Progression. Humans. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525494.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  •  go-up   go-down






Advertisement